

=> d his

(FILE 'HOME' ENTERED AT 08:35:27 ON 19 MAY 2005)

L1 FILE 'HCAPLUS' ENTERED AT 08:35:37 ON 19 MAY 2005
2 US20040241197/PN OR (DE2001-10136077# OR WO2002-EP8124#)/AP,PRN

FILE 'REGISTRY' ENTERED AT 08:37:49 ON 19 MAY 2005

L2 FILE 'HCAPLUS' ENTERED AT 08:37:51 ON 19 MAY 2005
TRA L1 1- RN : 2 TERMS

L3 FILE 'REGISTRY' ENTERED AT 08:37:51 ON 19 MAY 2005
2 SEA L2

L4 FILE 'WPIX' ENTERED AT 08:37:54 ON 19 MAY 2005
2 US20040241197/PN OR (DE2001-10136077# OR WO2002-EP8124#)/AP,PRN

=> b hcap

FILE 'HCAPLUS' ENTERED AT 08:38:31 ON 19 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 May 2005 VOL 142 ISS 21
FILE LAST UPDATED: 18 May 2005 (20050518/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all l1 tot

L1 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:117581 HCAPLUS
DN 138:158557
ED Entered STN: 14 Feb 2003
TI Cosmetic and dermatological preparations containing a combination of creatinine and creatine or their derivatives
IN Biergiesser, Helga; Blatt, Thomas; Kruse, Inge; Lenz, Holger; Mündt, Claudia; Schmidt, Melanie; Schoenrock, Uwe; Schreiner, Volker; Staeb, Franz
PA Beiersdorf AG, Germany
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA German
IC ICM A61K007-48
ICS A61P017-00; A61P017-02; A61P017-02; A61P017-06; A61P017-14; A61P017-16
CC 62-4 (Essential Oils and Cosmetics)
Section cross-reference(s): 63
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

Search done by Noble Jarrell

```

PI      WO 2003011242      A1      20030213      WO 2002-EP8125      20020722 <--
      W:  JP, US
      RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT,
      LU, MC, NL, PT, SE, SK, TR
      DE 10136077      A1      20030213      DE 2001-10136077      20010725 <--
      EP 1414402      A1      20040506      EP 2002-764746      20020722 <--
      R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
      IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
      JP 2005503373      T2      20050203      JP 2003-516474      20020722 <--
      US 2004241197      A1      20041202      US 2004-767962      20040126 <--
PRAI DE 2001-10136077      A      20010725 <--
      WO 2002-EP8124      A1      20020722 <--
      WO 2002-EP8125      W      20020722

```

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003011242	ICM	A61K007-48
	ICS	A61P017-00; A61P017-02; A61P017-02; A61P017-06; A61P017-14; A61P017-16
DE 10136077	ECLA	A61K008/43; A61Q017/00; A61Q019/00; A61Q019/08 <--
JP 2005503373	FTERM	4C083/AA122; 4C083/AB032; 4C083/AB212; 4C083/AB242; 4C083/AB342; 4C083/AB362; 4C083/AC012; 4C083/AC072; 4C083/AC092; 4C083/AC102; 4C083/AC122; 4C083/AC172; 4C083/AC182; 4C083/AC212; 4C083/AC242; 4C083/AC342; 4C083/AC352; 4C083/AC392; 4C083/AC402; 4C083/AC422; 4C083/AC442; 4C083/AC512; 4C083/AC532; 4C083/AC582; 4C083/AC741; 4C083/AC742; 4C083/AC851; 4C083/AC852; 4C083/AC862; 4C083/AD072; 4C083/AD092; 4C083/AD152; 4C083/AD162; 4C083/AD172; 4C083/AD202; 4C083/AD352; 4C083/AD512; 4C083/AD532; 4C083/AD632; 4C083/AD662; 4C083/BB51; 4C083/CC01; 4C083/CC02; 4C083/CC04; 4C083/CC05; 4C083/DD08; 4C083/DD11; 4C083/DD23; 4C083/DD31; 4C083/DD39; 4C083/DD41; 4C083/EE12; 4C083/EE13; 4C086/AA01; 4C086/AA02; 4C086/BC09; 4C086/DA40; 4C086/MA01; 4C086/MA02; 4C086/MA04; 4C086/MA10; 4C086/MA13; 4C086/MA16; 4C086/MA22; 4C086/MA23; 4C086/MA28; 4C086/MA34; 4C086/MA63; 4C086/NA14; 4C086/ZA89; 4C086/ZB22; 4C086/ZC41; 4C206/AA01; 4C206/AA02; 4C206/HA32; 4C206/MA01; 4C206/MA02; 4C206/MA04; 4C206/MA14; 4C206/MA24; 4C206/MA33; 4C206/MA37; 4C206/MA42; 4C206/MA43; 4C206/MA48; 4C206/MA54; 4C206/MA83; 4C206/NA14; 4C206/ZA89; 4C206/ZB22; 4C206/ZC41 <--
US 2004241197	NCL	424/401.000
	ECLA	A61K008/43; A61Q017/00; A61Q019/00; A61Q019/08 <--
AB		The invention relates to cosmetic or dermatol. prepsns. containing a combination of active ingredients consisting of creatinine and creatine or their derivs. The prepsns. are used for the treatment and prevention of dry skin, wound healing, itching, skin aging etc. Thus a PIT emulsion contained (weight/weight%): glycerin monostearate self-emulsifying 0.5; polyoxyethylene(30) cetylstearyl ether 5; cetyl alc. 2.5; diethylhexyl butamidotriazole 1; ethylhexyl triazole 4; phenylbenzimidazole sulfonic acid 0.5; titanium oxide 0.5; zinc oxide 2; butylene glycol dicaprylate/dicaprate 5; phenylmethylpolysiloxane 2; PVP hexadecene copolymer 0.5; glycerin 3; tocopherol acetate 0.5; creatine 0.2; creatinine 0.2; α-glucosylrutin 0.1; preservative q.s.; ethanol 3; perfume q.s.; water to 100.
ST		creatinine creatine cosmetic dermatol skin
IT		Skin, disease (aging; cosmetic and dermatol. prepsns. containing a combination of creatinine and creatine or their derivs.)
IT		Dermatitis (atopic; cosmetic and dermatol. prepsns. containing a combination of creatinine and creatine or their derivs.)
IT		Pruritus

Psoriasis
Seborrhea
Vitiligo
Wound healing

(cosmetic and dermatol. prepn. containing a combination of creatinine and creatine or their derivs.)

IT Cosmetics

(creams; cosmetic and dermatol. prepn. containing a combination of creatinine and creatine or their derivs.)

IT Skin, disease

(dry; cosmetic and dermatol. prepn. containing a combination of creatinine and creatine or their derivs.)

IT Cosmetics

(emulsions; cosmetic and dermatol. prepn. containing a combination of creatinine and creatine or their derivs.)

IT Cosmetics

(gels; cosmetic and dermatol. prepn. containing a combination of creatinine and creatine or their derivs.)

IT Cosmetics

(hydrodispersions; cosmetic and dermatol. prepn. containing a combination of creatinine and creatine or their derivs.)

IT Skin, disease

(light; cosmetic and dermatol. prepn. containing a combination of creatinine and creatine or their derivs.)

IT Skin, disease

(pigmentation; cosmetic and dermatol. prepn. containing a combination of creatinine and creatine or their derivs.)

IT Drug delivery systems

(topical; cosmetic and dermatol. prepn. containing a combination of creatinine and creatine or their derivs.)

IT 57-00-1, Creatine 57-00-1D, Creatine, derivs. 60-27-5, Creatinine 60-27-5D, Creatinine, derivs.

RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)

(cosmetic and dermatol. prepn. containing a combination of creatinine and creatine or their derivs.)

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Ajinomoto Co Inc; JP 63263060 A 1988 HCAPLUS
- (2) Anon; PATENT ABSTRACTS OF JAPAN 1989, V013(069), PC-569
- (3) Anon; PATENT ABSTRACTS OF JAPAN 2001, V2000(12)
- (4) Burke, D; JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL APPLICATIONS 1999, V732(2), P479 HCAPLUS
- (5) Charles, H; US 5968544 A 1999 HCAPLUS
- (6) Grasser, B; WO 02076408 A 2002
- (7) Heinz, K; WO 0059519 A 2000 HCAPLUS
- (8) Heinz, K; DE 19963628 A 2001
- (9) Howard Foundation; WO 02069740 A 2002 HCAPLUS
- (10) Lion Corp; JP 2000247866 A 2000 HCAPLUS
- (11) Sueddeutsche Kalkstickstoff; DE 19841385 A 2000 HCAPLUS

L1 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:117580 HCAPLUS

DN 138:158556

ED Entered STN: 14 Feb 2003

TI Cosmetic and dermatological preparations containing creatinine and/or its derivatives

IN Biergiesser, Helga; Blatt, Thomas; Kruse, Inge; Schmidt, Melanie; Schoenrock, Uwe; Staeb, Franz

PA Beiersdorf AG, Germany

SO PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DT Patent

LA German

IC ICM A61K007-48

ICS A61P017-00; A61P017-02; A61P017-06; A61P017-14; A61P017-16

CC 62-4 (Essential Oils and Cosmetics)
Section cross-reference(s): 63

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003011241	A1	20030213	WO 2002-EP8124	20020722 <--
	WO 2003011241	C1	20030320		
	W: JP, US				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
	DE 10136076	A1	20030213	DE 2001-10136076	20010725
	EP 1414401	A1	20040506	EP 2002-760258	20020722 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2004538299	T2	20041224	JP 2003-516473	20020722 <--
	US 2004241197	A1	20041202	US 2004-767962	20040126 <--
PRAI	DE 2001-10136076	A	20010725		
	DE 2001-10136077	A	20010725	<--	
	WO 2002-EP8124	W	20020722	<--	
	WO 2002-EP8125	A1	20020722		

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	WO 2003011241	ICM	A61K007-48
		ICS	A61P017-00; A61P017-02; A61P017-06; A61P017-14; A61P017-16
	DE 10136076	ECLA	A61K008/43; A61Q017/00; A61Q019/00; A61Q019/08
	JP 2004538299	FTERM	4C083/AB032; 4C083/AB212; 4C083/AB242; 4C083/AB342; 4C083/AB352; 4C083/AC012; 4C083/AC072; 4C083/AC092; 4C083/AC102; 4C083/AC122; 4C083/AC172; 4C083/AC182; 4C083/AC212; 4C083/AC242; 4C083/AC332; 4C083/AC342; 4C083/AC352; 4C083/AC392; 4C083/AC402; 4C083/AC422; 4C083/AC532; 4C083/AC581; 4C083/AC582; 4C083/AC851; 4C083/AC852; 4C083/AD072; 4C083/AD092; 4C083/AD152; 4C083/AD172; 4C083/AD352; 4C083/AD412; 4C083/AD532; 4C083/AD662; 4C083/BB41; 4C083/BB48; 4C083/CC04; 4C083/CC05; 4C083/DD27; 4C083/DD31; 4C083/DD32; 4C083/DD33; 4C083/DD34; 4C083/DD41; 4C083/EE12; 4C083/EE13; 4C083/EE22; 4C083/EE23; 4C086/AA01; 4C086/BC35; 4C086/MA02; 4C086/MA05; 4C086/MA17; 4C086/MA28; 4C086/MA63; 4C086/NA14; 4C086/ZA89; 4C086/ZA92; 4C086/ZC75; 4C206/AA01; 4C206/FA53; 4C206/MA02; 4C206/MA05; 4C206/MA37; 4C206/MA48; 4C206/MA83; 4C206/NA14; 4C206/ZA89; 4C206/ZA92; 4C206/ZC75 <--
	US 2004241197	NCL	424/401.000
		ECLA	A61K008/43; A61Q017/00; A61Q019/00; A61Q019/08 <--
AB	The invention relates to cosmetic or dermatol. preps. containing a combination of active ingredients consisting of creatinine and creatine or their derivs. The preps. are used for the treatment and prevention of dry skin, wound healing, itching, skin aging etc. Thus a PIT emulsion contained (weight/weight%): glycerin monostearate self-emulsifying 0.5; polyoxyethylene(30) cetylstearyl ether 5; cetyl alc. 2.5; diethylhexyl butamidotriazone 1; ethylhexyl triazone 4; phenylbenzimidazole sulfonic acid 0.5; titanium oxide 0.5; zinc oxide 2; butylene glycol dicaprylate/dicaprate 5; phenylmethylpolysiloxane 2; PVP hexadecene copolymer 0.5; glycerin 3; tocopherol acetate 0.5; creatine 0.2; creatinine 0.2; α -glucosylrutin 0.1; preservative q.s.; ethanol 3; perfume q.s.; water to 100.		
ST	creatinine creatine cosmetic dermatol skin		
IT	Skin, disease (aging; cosmetic and dermatol. preps. containing creatinine and/or its derivs.)		
IT	Dermatitis (atopic; cosmetic and dermatol. preps. containing creatinine and/or its derivs.)		

IT Pruritus
Psoriasis
Seborrhea
Vitiligo
Wound healing
(cosmetic and dermatol. prepn. containing creatinine and/or its derivs.)

IT Cosmetics
(creams; cosmetic and dermatol. prepn. containing creatinine and/or its derivs.)

IT Skin, disease
(dry; cosmetic and dermatol. prepn. containing creatinine and/or its derivs.)

IT Cosmetics
(emulsions; cosmetic and dermatol. prepn. containing creatinine and/or its derivs.)

IT Cosmetics
(gels; cosmetic and dermatol. prepn. containing creatinine and/or its derivs.)

IT Cosmetics
(hydrodispersions; cosmetic and dermatol. prepn. containing creatinine and/or its derivs.)

IT Skin, disease
(light; cosmetic and dermatol. prepn. containing creatinine and/or its derivs.)

IT Skin, disease
(pigmentation; cosmetic and dermatol. prepn. containing creatinine and/or its derivs.)

IT Drug delivery systems
(topical; cosmetic and dermatol. prepn. containing creatinine and/or its derivs.)

IT 57-00-1, Creatine 57-00-1D, Creatine, derivs. 60-27-5, Creatinine
60-27-5D, Creatinine, derivs.
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(cosmetic and dermatol. prepn. containing creatinine and/or its derivs.)

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Ajinomoto Co Inc; JP 63263060 A 1988 HCAPLUS
- (2) Anon; PATENT ABSTRACTS OF JAPAN 1989, V013(069), PC-569
- (3) Anon; PATENT ABSTRACTS OF JAPAN 2001, V2000(12)
- (4) Burke, D; JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL APPLICATIONS 1999, V732(2), P479 HCAPLUS
- (5) Charles, H; US 5968544 A 1999 HCAPLUS
- (6) Grasser, B; WO 02076408 A 2002
- (7) Heinz, K; WO 0059519 A 2000 HCAPLUS
- (8) Heinz, K; DE 19963628 A 2001
- (9) Howard Foundation; WO 02069740 A 2002 HCAPLUS
- (10) Lion Corp; JP 2000247866 A 2000 HCAPLUS
- (11) Sueddeutsche Kalkstickstoff; DE 19841385 A 2000 HCAPLUS

=> b reg

FILE 'REGISTRY' ENTERED AT 08:38:40 ON 19 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 MAY 2005 HIGHEST RN 850688-83-4
DICTIONARY FILE UPDATES: 18 MAY 2005 HIGHEST RN 850688-83-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.


*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d ide l3 tot

L3 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2005 ACS on STN
RN 60-27-5 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4H-Imidazol-4-one, 2-amino-1,5-dihydro-1-methyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Creatinine (8CI)
OTHER NAMES:
CN 1-Methylglycocyamidine
CN 1-Methylhydantoin-2-imide
CN 2-Amino-1-methyl-1,5-dihydroimidazol-4-one
CN 2-Amino-1-methylimidazolin-4-one
CN NSC 13123
CN TEGO Cosmo C 250
FS 3D CONCORD
DR 15231-31-9, 82016-55-5, 45514-66-7
MF C4 H7 N3 O
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PIRA, PROMT, SPECINFO, TOXCENTER, ULIDAT, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

13892 REFERENCES IN FILE CA (1907 TO DATE)
54 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

Search done by Noble Jarrell

13933 REFERENCES IN FILE CAPLUS (1907 TO DATE)
6 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L3 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2005 ACS on STN
RN 57-00-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Creatine (8CI)
OTHER NAMES:
CN Cosmocair C 100.
CN Methylguanidoacetic acid
CN N-Methyl-N-guanylglycine
CN NSC 8752
CN Phosphagen
FS 3D CONCORD
MF C4 H9 N3 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN,
CHEMCATS, CHEMLIST, CIN, CSCHM, DDFU, DETHERM*, DIOGENES, DRUGU,
EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*,
MSDS-OHS, NAPRALERT, NIOSHTIC, PROMT, SPECINFO, TOXCENTER, TULSA,
USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5893 REFERENCES IN FILE CA (1907 TO DATE)
114 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
5905 REFERENCES IN FILE CAPLUS (1907 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> b wpix

FILE 'WPIX' ENTERED AT 08:38:44 ON 19 MAY 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 17 MAY 2005 <20050517/UP>
MOST RECENT DERWENT UPDATE: 200531 <200531/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
GUIDES, PLEASE VISIT:
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
FIRST VIEW - FILE WPIFV.

Search done by Noble Jarrell

FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.

PLEASE CHECK:

<http://thomsonderwent.com/support/dwpioref/reftools/classification/code-revision/>
FOR DETAILS. <<<

=> d all dcn drn l4 tot

L4 ANSWER 1 OF 2 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2003-291237 [29] WPIX
CR 2003-291236 [29]
DNC C2003-075886
TI Cosmetic or dermatological preparations containing creatinine and
creatine, useful e.g. for combating skin aging symptoms or treating
inflammatory conditions such as eczema or psoriasis.
DC B03 D21 E13
IN BIERGIESSE, H; BLATT, T; KRUSE, I; LENZ, H; MUNDT, C; SCHMIDT, M;
SCHOENROCK, U; SCHREINER, V; STAEB, F; SCHONROCK, U; STAB, F
PA (BEIE) BEIERSDORF AG
CYC 32
PI DE 10136077 A1 20030213 (200329)* 15 A61K007-48
WO 2003011242 A1 20030213 (200329) GE A61K007-48
RW: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK
TR
W: JP US
EP 1414402 A1 20040506 (200430) GE A61K007-48
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LT LU LV MC
MK NL PT RO SE SI SK TR
US 2004241197 A1 20041202 (200481) A61K007-00 <--
JP 2005503373 W 20050203 (200516) 55 A61K007-00
ADT DE 10136077 A1 DE 2001-10136077 20010725; WO 2003011242 A1 WO
2002-EP8125 20020722; EP 1414402 A1 EP 2002-764746 20020722, WO
2002-EP8125 20020722; US 2004241197 A1 Cont of WO 2002-EP8124
20020722, Cont of WO 2002-EP8125 20020722, US 2004-767962 20040126;
JP 2005503373 W WO 2002-EP8125 20020722, JP 2003-516474 20020722
FDT EP 1414402 A1 Based on WO 2003011242; JP 2005503373 W Based on WO
2003011242
PRAI DE 2001-10136077 20010725
IC ICM A61K007-00; A61K007-48
ICS A61K031-198; A61K031-4168; A61K031-664; A61P017-00; A61P017-02;
A61P017-04; A61P017-06; A61P017-14; A61P017-16
AB DE 10136077 A UPAB: 20050308
NOVELTY - Cosmetic or dermatological preparations (A) containing a
combination of creatinine (and/or its derivatives) (I) and creatine
(and/or its derivatives) (II) are new.
ACTIVITY - Dermatological; Antiallergic; Antiinflammatory;
Antipsoriatic; Antipruritic; Antiseborrheic; Immunosuppressant;
Immunostimulant; Vulnerary; Antialopecia.
No suitable biological data available.
MECHANISM OF ACTION - Ceramide biosynthesis promoter; proteolytic
enzyme inhibitor; intracellular DNA synthesis promoter; fibroblast and
keratinocyte proliferation and differentiation promoter; antiradical.
USE - The use of (A) is claimed for: (a) treatment and/or prophylaxis
of inflammatory skin conditions and/or protection of skin against
sensitivity and dryness (e.g. for combating atopic or seborrheic eczema,
polymorphic light dermatosis, psoriasis, vitiligo, wound healing
deficiency, pruritis, sensitive or irritated skin, light-induced
immunosuppression, sensitive or hypoactive states of the skin or
exoskeleton or abnormalities in desquamation or fibroblast and
keratinocyte proliferation or differentiation); (b) treatment and/or
prophylaxis of intrinsic and/or extrinsic skin aging and/or UV induced
skin damage (e.g. for combating skin degeneration symptoms (such as
age-spots, wrinkles, teleangiectasis, slackness, loss of elasticity,
atrophy of the epidermis, dermis, connective tissue and capillaries,
'fatigue' and loss of luster), hyperactivity of proteolytic enzymes (e.g.

metalloproteases), disorders in normal collagen, hyaluronic acid, elastin and glucosaminoglycan homeostasis, intracellular DNA synthesis insufficiency (especially deficit or hypoactive states of the skin) or the effects on the skin or exoskeleton of environmental agents (e.g. smoke, smog, reactive oxygen species or free radicals)); (c) treatment and/or prophylaxis of pigmentation disorders; (d) promotion of ceramide biosynthesis (e.g. for combating abnormalities in ceramide, lipid and energy metabolism in the skin); (e) reinforcement of the barrier function of skin (e.g. for combating stratum corneum dysfunction of abnormalities in lipid peroxidation, transepidermal water loss and skin moisture content); (f) treatment and/or prophylaxis of disorders in skin pH and osmolyte balance); (g) treatment and/or prophylaxis of deficient intracellular communication in the skin (including communication via mediators and/or mechanical/physiological compounds; or (h) treatment and/or prophylaxis of functional disorders of the exoskeleton (e.g. hair loss, hair growth deficiency, seborrhea, greasy skin or hair, comedones or dandruff).

ADVANTAGE - The (I)/(II) combination has a strong and lasting beneficial effect against a wide range of skin conditions (e.g. aging symptoms and UV- or ozone-induced damage) and is free of side-effects.
Dwg.0/0

FS

CPI

FA

AB; DCN

MC

CPI: B07-D09; B10-A17; B14-C03; B14-G01; B14-G02; B14-G02A; B14-N17;
B14-N17A; B14-N17B; B14-N17C; B14-N17D; D08-B; D08-B09; D08-B10;
E07-D; E07-D09B

M2 *01* DCN: R00203-K; R00203-T; R00203-M

M2 *02* DCN: R00118-K; R00118-T; R00118-M

M3 *01* DCN: R00203-K; R00203-T; R00203-M

M3 *02* DCN: R00118-K; R00118-T; R00118-M

DRN

0118-U; 0203-U

L4 ANSWER 2 OF 2 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2003-291236 [29] WPIX

CR 2003-291237 [29]

DNC C2003-075885

TI Cosmetic or dermatological preparations containing creatinine or its derivative, useful e.g. for combating skin aging symptoms or treating inflammatory conditions such as eczema or psoriasis.

DC B03 D21 E13

IN BIERGIESSER, H; BLATT, T; KRUSE, I; SCHMIDT, M; SCHOENROCK, U; STAEB, F

PA (BEIE) BEIERSDORF AG

CYC 32

PI DE 10136076 A1 20030213 (200329)* 16 A61K007-48

WO 2003011241 A1 20030213 (200329) GE A61K007-48

RW: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK

TR

W: JP US.

EP 1414401 A1 20040506 (200430) GE A61K007-48

R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LT LU LV MC

MK NL PT RO SE SI SK TR

JP 2004538299 W 20041224 (200502) 57 A61K007-48

ADT DE 10136076 A1 DE 2001-10136076 20010725; WO 2003011241 A1 WO

2002-EP8124 20020722; EP 1414401 A1 EP 2002-760258 20020722, WO

2002-EP8124 20020722; JP 2004538299 W WO 2002-EP8124 20020722

, JP 2003-516473 20020722

FDT EP 1414401 A1 Based on WO 2003011241; JP 2004538299 W Based on WO
2003011241

PRAI DE 2001-10136076 20010725

IC ICM A61K007-48

ICS A61K007-00; A61K031-198; A61K031-4168; A61P017-00; A61P017-02;

A61P017-06; A61P017-14; A61P017-16; A61P043-00

AB

DE 10136076 A UPAB: 20050107

NOVELTY - Cosmetic or dermatological preparations (A) containing
creatinine (and/or its derivatives) (I) are new.

ACTIVITY - Dermatological; Antiallergic; Antiinflammatory;

Antipsoriatic; Antipruritic; Antiseborrheic; Immunosuppressant;
Immunostimulant; Vulnerary; Antialopecia.

No suitable biological data given.

MECHANISM OF ACTION - Ceramide biosynthesis promoter; proteolytic enzyme inhibitor; intracellular DNA synthesis promoter; fibroblast and keratinocyte proliferation and differentiation promoter; antiradical.

USE - The use of (A) is claimed for: (a) treatment and/or prophylaxis of inflammatory skin conditions and/or protection of skin against sensitivity and dryness (e.g. for combating atopic or seborrheic eczema, polymorphic light dermatosis, psoriasis, vitiligo, wound healing deficiency, pruritis, sensitive or irritated skin, light-induced immunosuppression, sensitive or hypoactive states of the skin or exoskeleton or abnormalities in desquamation or fibroblast and keratinocyte proliferation or differentiation); (b) treatment and/or prophylaxis of intrinsic and/or extrinsic skin aging and/or UV induced skin damage (e.g. for combating skin degeneration symptoms (such as age-spots, wrinkles, teleangiectasis, slackness, loss of elasticity, atrophy of the epidermis, dermis, connective tissue and capillaries, 'fatigue' and loss of luster), hyperactivity of proteolytic enzymes (e.g. metalloproteases), disorders in normal collagen, hyaluronic acid, elastin and glucosaminoglycan homeostasis, intracellular DNA synthesis insufficiency (especially deficit or hypoactive states of the skin) or the effects on the skin or exoskeleton of environmental agents (e.g. smoke, smog, reactive oxygen species or free radicals)); (c) treatment and/or prophylaxis of pigmentation disorders; (d) promotion of ceramide biosynthesis (e.g. for combating abnormalities in ceramide, lipid and energy metabolism in the skin); (e) reinforcement of the barrier function of skin (e.g. for combating stratum corneum dysfunction of abnormalities in lipid peroxidation, transepidermal water loss and skin moisture content); (f) treatment and/or prophylaxis of disorders in skin pH and osmolyte balance); (g) treatment and/or prophylaxis of deficient intracellular communication in the skin (including communication via mediators and/or mechanical/physiological compounds; or (h) treatment and/or prophylaxis of functional disorders of the exoskeleton (e.g. hair loss, hair growth deficiency, seborrhea, greasy skin or hair, comedones or dandruff)).

ADVANTAGE - (I) has a strong and lasting beneficial effect against a wide range of skin conditions (e.g. aging symptoms and UV- or ozone-induced damage) and is free of side-effects.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B07-D09; B14-C03; B14-G01; B14-G02; B14-G02A; B14-N17; B14-N17B;
B14-N17C; B14-N17D; B14-R01; B14-R02; D08-B; D08-B09A; D08-B10;
E07-D; E07-D09

M2 *01* DCN: R00203-K; R00203-T; R00203-U

M3 *01* DCN: R00203-K; R00203-T; R00203-U

DRN 0203-U

=> b home

FILE 'HOME' ENTERED AT 08:39:09 ON 19 MAY 2005

=>

=> b reg

FILE 'REGISTRY' ENTERED AT 14:01:13 ON 19 MAY 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 MAY 2005 HIGHEST RN 850688-83-4

DICTIONARY FILE UPDATES: 18 MAY 2005 HIGHEST RN 850688-83-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.


```
*****
*
* The CA roles and document type information have been removed from
* the IDE default display format and the ED field has been added,
* effective March 20, 2005. A new display format, IDERL, is now
* available and contains the CA role and document type information.
*
*****
```

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d que sta l11

L9 STR



VAR G1=OH/10

VAR G2=12/13

NODE ATTRIBUTES:

CONNECT IS M1 RC AT 12

CONNECT IS M1 RC AT 13

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L11 141 SEA FILE=REGISTRY CSS FUL L9

100.0% PROCESSED 880 ITERATIONS

141 ANSWERS

SEARCH TIME: 00.00.01

=> b home

FILE 'HOME' ENTERED AT 14:01:20 ON 19 MAY 2005

Search done by Noble Jarrell

=>

=> b reg

FILE 'REGISTRY' ENTERED AT 08:59:49 ON 19 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 MAY 2005 HIGHEST RN 850688-83-4
DICTIONARY FILE UPDATES: 18 MAY 2005 HIGHEST RN 850688-83-4.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d ide l8 tot

L8 ANSWER 1 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 831209-37-1 REGISTRY
ED Entered STN: 15 Feb 2005
CN 4H-Imidazol-4-one, 2-amino-1,5-dihydro-1-methyl-, monohydrate (9CI) (CA
INDEX NAME)
MF C4 H7 N3 O . H2 O
SR CA
LC STN Files: CA, CAPLUS
CRN (60-27-5)




● H2O

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

Search done by Noble Jarrell

L8 ANSWER 2 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 831209-35-9 REGISTRY
ED Entered STN: 15 Feb 2005
CN 4H-Imidazol-4-one, 2-amino-1,5-dihydro-1-methyl-, conjugate monoacid,
monohydrate (9CI) (CA INDEX NAME)
MF C4 H7 N3 O . H2 O . H
SR CA
LC STN Files: CA, CAPLUS
CRN (60-27-5)




● H⁺

● H₂O


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 3 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 793626-27-4 REGISTRY
ED Entered STN: 06 Dec 2004
CN 4H-Imidazol-4-one-4-¹⁴C, 2-amino-1,5-dihydro-1-methyl- (9CI) (CA INDEX
NAME)
FS 3D CONCORD
MF C4 H7 N3 O
CI COM
SR CA




L8 ANSWER 4 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 763885-49-0 REGISTRY
ED Entered STN: 15 Oct 2004
CN 4-Imidazolidinone, 2-imino-1-methyl- (9CI) (CA INDEX NAME)
MF C4 H7 N3 O
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L8 ANSWER 5 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 616875-85-5 REGISTRY
 ED Entered STN: 14 Nov 2003
 CN 1H-Imidazol-4-ol, 2-amino-1-methyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C4 H7 N3 O
 SR CA
 LC STN Files: CA, CAPLUS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 6 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 340728-83-8 REGISTRY
 ED Entered STN: 12 Jun 2001
 CN 4H-Imidazol-4-one, 2-amino-3,5-dihydro-3-(methyl-13C)- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C4 H7 N3 O
 SR CAS Client Services




L8 ANSWER 7 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 336804-82-1 REGISTRY
 ED Entered STN: 21 May 2001
 CN 4H-Imidazol-4-one-2-14C, 2-amino-1,5-dihydro-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)
 MF C4 H7 N3 O . Cl H
 SR CAS Client Services
 CRN (100482-09-5)



● HCl


L8 ANSWER 8 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 257869-50-4 REGISTRY
ED Entered STN: 02 Mar 2000
CN 4H-Imidazol-4-one, 2-amino-3,5-dihydro-3-methyl-, monohydrochloride (9CI)
(CA INDEX NAME)
MF C4 H7 N3 O . Cl H
SR CA
LC STN Files: CA, CAPLUS, CASREACT
CRN (34293-24-8)



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L8 ANSWER 9 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 213411-68-8 REGISTRY
ED Entered STN: 29 Oct 1998
CN 4H-Imidazol-4-one, 2-amino-1,5-dihydro-1-methyl-, tetrahydrochloride (9CI)
(CA INDEX NAME)
OTHER NAMES:
CN Creatinine tetrahydrochloride
MF C4 H7 N3 O . 4 Cl H
SR CA
LC STN Files: CA, CAPLUS
CRN (60-27-5)



● 4 HCl


1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 10 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 146528-05-4 REGISTRY
ED Entered STN: 19 Mar 1993
CN 4H-Imidazol-4-one, 2-amino-1,5-dihydro-1-methyl-, labeled with carbon-13
(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C4 H7 N3 O
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
IL XC-13




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 11 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 146490-60-0 REGISTRY
ED Entered STN: 17 Mar 1993
CN 4H-Imidazol-4-one-18O, 2-amino-1,5-dihydro-1-methyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C4 H7 N3 O
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 12 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 146490-59-7 REGISTRY
ED Entered STN: 17 Mar 1993
CN 4H-Imidazol-4-one, 2-amino-1,5-dihydro-1-methyl-, labeled with nitrogen-15
(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C4 H7 N3 O
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
IL XN-15




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 13 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 117599-10-7 REGISTRY
ED Entered STN: 18 Nov 1988
CN Thiazolium, 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-4-methyl-5-(4,6,6-trihydroxy-4,6-dioxo-3,5-dioxo-4,6-diphosphahex-1-yl)-, chloride, mixt. with 2-amino-1,5-dihydro-1-methyl-4H-imidazol-4-one (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 4H-Imidazol-4-one, 2-amino-1,5-dihydro-1-methyl-, mixt. contg. (9CI)
CN Thiazolium, 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-4-methyl-5-(4,6,6-trihydroxy-3,5-dioxo-4,6-diphosphahex-1-yl)-, chloride, P,P'-dioxide, mixt. with 2-amino-1,5-dihydro-1-methyl-4H-imidazol-4-one
MF C12 H19 N4 O7 P2 S . C4 H7 N3 O . Cl
CI MXS
SR CA
LC STN Files: CA, CAPLUS

CM 1


CRN 154-87-0 (136-08-3)
CMF C12 H19 N4 O7 P2 S . Cl



● Cl⁻

CM 2

CRN 60-27-5
CMF C4 H7 N3 O




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 14 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN

Search done by Noble Jarrell

RN 84137-93-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4H-Imidazol-4-one, 2-amino-1,5-dihydro-1-methyl-, labeled with deuterium
(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C4 H7 N3 O
CI COM
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
IL XH-2




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 15 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 66224-89-3 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4H-Imidazol-4-one, 2-amino-1,5-dihydro-1-methyl-, mononitrate (9CI) (CA
INDEX NAME)
MF C4 H7 N3 O . H N O3
LC STN Files: CA, CAPLUS


CM 1

CRN 7697-37-2
CMF H N O3



CM 2


CRN 60-27-5
CMF C4 H7 N3 O



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L8 ANSWER 16 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 62036-69-5 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4H-Imidazol-4-one, 2-(amino-15N)-1,5-dihydro-1-methyl- (9CI) (CA INDEX
NAME)
MF C4 H7 N3 O
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT

(*File contains numerically searchable property data)




2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 17 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 58472-67-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4H-Imidazol-4-one, 2-amino-1,5-dihydro-1-methyl-, conjugate monoacid (9CI)
(CA INDEX NAME)
MF C4 H7 N3 O . H
LC STN Files: CA, CAPLUS
CRN (60-27-5)

● H⁺

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 18 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 58472-66-5 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4H-Imidazol-4-one, 2-amino-3,5-dihydro-3-methyl-, conjugate monoacid (9CI)
(CA INDEX NAME)
MF C4 H7 N3 O . H
LC STN Files: CA, CAPLUS
CRN (34293-24-8)


● H⁺

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 19 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 37429-49-5 REGISTRY


Search done by Noble Jarrell

ED Entered STN: 16 Nov 1984
CN 4H-Imidazol-4-one-4-¹³C, 2-amino-1,5-dihydro-1-methyl- (9CI) (CA INDEX NAME)
MF C4 H7 N3 O
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 20 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 34293-24-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4H-Imidazol-4-one, 2-amino-3,5-dihydro-3-methyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Imidazolin-5-one, 2-amino-1-methyl- (8CI)
OTHER NAMES:
CN 2-Imino-3-methyl-4-imidazolidinone
FS 3D CONCORD
MF C4 H7 N3 O
CI COM
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMINFORMRX, IFICDB, IFIPAT, IFIUDB, USPATFULL
(*File contains numerically searchable property data)




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1907 TO DATE)
8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 21 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 31377-28-3 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4H-Imidazol-4-one, 2-amino-1,5-dihydro-1-methyl-, sulfate (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Creatinine, sulfate (1:1) (8CI)
OTHER NAMES:
CN Creatinine sulfate
DR 27849-70-3, 30386-94-8
MF C4 H7 N3 O . H2 O4 S
CI COM
LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS, CHEMCATS, CSCHEM, EMBASE, NIOSHTIC, TOXCENTER
(*File contains numerically searchable property data)


CM 1

CRN 7664-93-9
CMF H2 O4 S




CM 2

CRN 60-27-5
CMF C4 H7 N3 O



21 REFERENCES IN FILE CA (1907 TO DATE)
21 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L8 ANSWER 22 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 28639-74-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4-Imidazolidinone, 2-amino-3-methyl-, hydrochloride (8CI) (CA INDEX NAME)
MF C4 H7 N3 O . x Cl H
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)
CRN (34293-24-8)



●x HCl


1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 23 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 21813-97-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4H-Imidazol-4-one, 2-amino-3,5-dihydro-3-(methyl-14C)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Creatinine-methyl-14C (8CI)
MF C4 H7 N3 O
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 24 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 19230-81-0 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4H-Imidazol-4-one, 2-amino-1,5-dihydro-1-methyl-, monohydrochloride (9CI)
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Imidazolin-4-one, 2-amino-1-methyl-, monohydrochloride (8CI)
CN Creatinine, monohydrochloride (8CI)
OTHER NAMES:
CN Creatinine hydrochloride
MF C4 H7 N3 O . Cl H
CI COM
LC STN Files: BEILSTEIN*, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS,
CHEMLIST, CSCHM, EMBASE, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (60-27-5)




● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

19 REFERENCES IN FILE CA (1907 TO DATE)
19 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L8 ANSWER 25 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 15366-31-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4H-Imidazol-4-one, 2-amino-1,5-dihydro-1-methyl-, monohydrobromide (9CI)
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Creatinine, monohydrobromide (8CI)
MF C4 H7 N3 O . Br H
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
(*File contains numerically searchable property data)
CRN (60-27-5)




● HBr

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 26 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 15041-04-0 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4H-Imidazol-4-one, 2-amino-1,5-dihydro-1-methyl-, labeled with tritium
(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C4 H7 N3 O
CI COM
IL XH-3




L8 ANSWER 27 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 15041-03-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4H-Imidazol-4-one, 2-amino-1,5-dihydro-1-methyl-, labeled with carbon-14
(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C4 H7 N3 O
IL C-14



L8 ANSWER 28 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 10448-78-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4H-Imidazol-4-one, 2-amino-1,5-dihydro-1-methyl-, sulfate (9CI) (CA INDEX
NAME)
MF C4 H7 N3 O . x H2 O4 S
LC STN Files: BEILSTEIN*
(*File contains numerically searchable property data)


CM 1

CRN 7664-93-9
CMF H2 O4 S



CM 2


CRN 60-27-5
CMF C4 H7 N3 O



L8 ANSWER 29 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 3670-40-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4H-Imidazol-4-one, 2-amino-1,5-dihydro-1-methyl-, phosphate (9CI) (CA
INDEX NAME)
MF C4 H7 N3 O . x H3 O4 P
LC STN Files: BEILSTEIN*, BIOSIS, CAOLD, TOXCENTER
(*File contains numerically searchable property data)


CM 1

CRN 7664-38-2
CMF H3 O4 P



CM 2


CRN 60-27-5
CMF C4 H7 N3 O



1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

Search done by Noble Jarrell

L8 ANSWER 30 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 60-27-5 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 4H-Imidazol-4-one, 2-amino-1,5-dihydro-1-methyl- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Creatinine (8CI)
 OTHER NAMES:
 CN 1-Methylglycocyamidine
 CN 1-Methylhydantoin-2-imide
 CN 2-Amino-1-methyl-1,5-dihydroimidazol-4-one
 CN 2-Amino-1-methylimidazolin-4-one
 CN NSC 13123
 CN TEGO Cosmo C 250
 FS 3D CONCORD
 DR 15231-31-9, 82016-55-5, 45514-66-7
 MF C4 H7 N3 O
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,
 CHEMINFORMRX, CHEMLIST, CIN, CSCHM, CSNB, DDFU, DETHERM*, DIOGENES,
 DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE,
 MRCK*, MSDS-OHS, NIOSHTIC, PIRA, PROMT, SPECINFO, TOXCENTER, ULIDAT,
 USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

13892 REFERENCES IN FILE CA (1907 TO DATE)
 54 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 13933 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 6 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> d his full

(FILE 'HOME' ENTERED AT 08:35:27 ON 19 MAY 2005)

L1 FILE 'HCAPLUS' ENTERED AT 08:35:37 ON 19 MAY 2005
 2 SEA ABB=ON PLU=ON US20040241197/PN OR (DE2001-10136077# OR
 WO2002-EP8124#)/AP,PRN

FILE 'REGISTRY' ENTERED AT 08:37:49 ON 19 MAY 2005

L2 FILE 'HCAPLUS' ENTERED AT 08:37:51 ON 19 MAY 2005
 TRA L1 1- RN : 2 TERMS

L3 FILE 'REGISTRY' ENTERED AT 08:37:51 ON 19 MAY 2005
 2 SEA ABB=ON PLU=ON L2

L4 FILE 'WPIX' ENTERED AT 08:37:54 ON 19 MAY 2005
 2 SEA ABB=ON PLU=ON US20040241197/PN OR (DE2001-10136077# OR
 WO2002-EP8124#)/AP,PRN

Search done by Noble Jarrell

FILE 'REGISTRY' ENTERED AT 08:41:47 ON 19 MAY 2005

L5 256 SEA ABB=ON PLU=ON C4H7N3O AND NCNC2/ES
L6 QUE ABB=ON PLU=ON (PMS OR MAN OR IDS)/CI OR COMPD OR
COMPOUND OR UNSPECIFIED OR (D OR T)/ELS
L7 63 SEA ABB=ON PLU=ON L5 NOT L6
SEL RN 1-3 5 8 11 13-15 20-23 37 40 42 44-45 50 52-53 55-63 L7
L8 30 SEA ABB=ON PLU=ON (10448-78-9/BI OR 117599-10-7/BI OR
146490-59-7/BI OR 146490-60-0/BI OR 146528-05-4/BI OR 15041-03-
9/BI OR 15041-04-0/BI OR 15366-31-1/BI OR 19230-81-0/BI OR
213411-68-8/BI OR 21813-97-8/BI OR 257869-50-4/BI OR 28639-74-9
/BI OR 31377-28-3/BI OR 336804-82-1/BI OR 340728-83-8/BI OR
34293-24-8/BI OR 3670-40-4/BI OR 37429-49-5/BI OR 58472-66-5/BI
OR 58472-67-6/BI OR 60-27-5/BI OR 616875-85-5/BI OR 62036-69-5
/BI OR 66224-89-3/BI OR 763885-49-0/BI OR 793626-27-4/BI OR
831209-35-9/BI OR 831209-37-1/BI OR 84137-93-9/BI) AND L7
SAV TEM L8 HAR962C1/A
L9 STR
L10 4 SEA CSS SAM L9
L11 141 SEA CSS FUL L9
L12 0 SEA ABB=ON PLU=ON L5 AND L11
SEL RN L11
L13 0 SEA ABB=ON PLU=ON (100482-07-3/CRN OR 100482-08-4/CRN OR
10237-47-5/CRN OR 102601-28-5/CRN OR 108795-66-0/CRN OR
113443-46-2/CRN OR 132478-02-5/CRN OR 135202-39-0/CRN OR
143827-19-4/CRN OR 14784-96-4/CRN OR 15041-01-7/CRN OR
15041-02-8/CRN OR 151301-14-3/CRN OR 15366-29-7/CRN OR
15366-30-0/CRN OR 15366-32-2/CRN OR 154605-64-8/CRN OR
17050-09-8/CRN OR 176110-79-5/CRN OR 176110-80-8/CRN OR
176950-40-6/CRN OR 176950-41-7/CRN OR 176950-42-8/CRN OR
176950-43-9/CRN OR 177024-62-3/CRN OR 201790-31-0/CRN OR
208535-04-0/CRN OR 208535-05-1/CRN OR 208535-06-2/CRN OR
209587-91-7/CRN OR 211504-83-5/CRN OR 211504-84-6/CRN OR
211504-85-7/CRN OR 221276-55-7/CRN OR 23067-41-6/CRN OR
245758-16-1/CRN OR 248914-29-6/CRN OR 284664-86-4/CRN OR
286437-18-1/CRN OR 286437-19-2/CRN OR 306274-40-8/CRN OR
306274-41-9/CRN OR 306274-42-0/CRN OR 306274-43-1/CRN OR
306274-44-2/CRN OR 306274-45-3/CRN OR 306274-46-4/CRN OR
306274-47-5/CRN OR 315669-77-3/CRN OR 315669-78-4/CRN OR
315669-79-5/CRN OR 3267-53-6/CRN OR 329244-66-8/CRN OR
329244-69-1/CRN OR 329244-74-8/CRN OR 329244-76-0/CRN OR
329244-82-8/CRN OR 329244-84-0/CRN OR 329244-92-0/CRN OR
331942-93-9/CRN OR 331942-94-0/CRN OR 335081-01-1/CRN OR
335158-50-4/CRN OR 336804-77-4/CRN OR 341553-87-5/CRN OR
341553-88-6/CRN OR 3545-30-0/CRN OR 380908-01-0/CRN OR
380908-02-1/CRN OR 404576-00-7/CRN OR 404576-01-8/CRN OR
404576-02-9/CRN OR 404576-03-0/CRN OR 404576-04-1/CRN OR
404576-05-2/CRN OR 404576-06-3/CRN OR 404576-07-4/CRN OR
404576-08-5/CRN OR 440632-86-0/CRN OR 463297-56-5/CRN OR
463943-12-6/CRN OR 463943-28-4/CRN OR 463943-44-4/CRN OR
484052-21-3/CRN OR 49540-45-6/CRN OR 49719-59-7/CRN OR
544675-15-2/CRN OR 544675-16-3/CRN OR 544675-17-4/CRN OR
544675-18-5/CRN OR 544675-19-6/CRN OR 544675-23-2/CRN OR
544675-25-4/CRN OR 544675-27-6/CRN OR 544675-29-8/CR
SAV TEM L11 HAR962C2/A

FILE 'HCAPLUS' ENTERED AT 09:00:39 ON 19 MAY 2005

L14 35809 SEA ABB=ON PLU=ON L8 OR IMIDAZOL? (1A) ONE (4A) AMINO (2A)
(DIHYDRO OR DI (1A) HYDRO?) (1A) METHYL OR IMIDAZOL? (3A)
(IMINO OR AMINO) (1A) METHYL OR IMIDAZOL? (1A) OL (1A) AMINO
(5A) METHYL OR CREATININE OR METHYLGLYCOCYAMIDINE OR METHYL
(1A) (GLYCOAMIDINE OR GLYCO? (1A) AMIDINE)
L15 6 SEA ABB=ON PLU=ON (METHYLHYDANTOIN? OR METHYL (1A) HYDANTION?
) (1A) IMIDE OR AMINO (1A) (METHYLIMIDAZOLIN? (1A) ONE OR
METHYL (2A) (DIHYDROIMIDAZOL? (1A) ONE OR (DIHYDRO OR DI (1A)
HYDRO?) (1A) IMIDAZOL?)) (1A) ONE OR NSC13123 OR NSC (1A)

(13123 OR 13 (1A) 123) OR TEGO? (1A) COSMO?
 E CREATININE/CT
 E E3+ALL

L16 15749 SEA ABB=ON PLU=ON CREATININE+NT/CT
 L17 26605 SEA ABB=ON PLU=ON L11 OR GLYCINE (2A) (AMINOIMINOMETHYL OR
 AMINO (1A) (IMINOMETHYL OR IMINO (1A) METHYL)) (1A) N (1A)
 METHYL OR CREATINE OR COSMOCAIR? OR METHYLGUANIDOACETIC (1A)
 ACID OR METHYLGUANIDO (1A) ACETIC (1A) ACID OR N (1A) METHYL
 (1A) N (1A) (GUANYLGLYCINE OR GUANYL (1A) GLYCINE)

L18 795 SEA ABB=ON PLU=ON NSC8752 OR NSC (1A) 8752 OR PHOSPHAGEN?
 E CREATINE/CT
 E E3+ALL

L19 5905 SEA ABB=ON PLU=ON CREATINE/CT
 L20 1734 SEA ABB=ON PLU=ON BEIERSDORF/CS, PA
 E BIERGIESSER H/AU

L21 28 SEA ABB=ON PLU=ON "BIERGIESSER HELGA"/AU
 E BLATT T/AU

L22 57 SEA ABB=ON PLU=ON ("BLATT T"/AU OR "BLATT THOMAS"/AU)
 E KRUSE I/AU

L23 60 SEA ABB=ON PLU=ON ("KRUSE I"/AU OR "KRUSE INGE"/AU OR "KRUSE
 INGER"/AU)
 E LENZ H/AU

L24 100 SEA ABB=ON PLU=ON ("LENZ H"/AU OR "LENZ H C"/AU OR "LENZ H
 H"/AU OR "LENZ H J"/AU OR "LENZ H JUERGEN"/AU OR "LENZ H
 JURGEN"/AU OR "LENZ H L B"/AU OR "LENZ H M"/AU OR "LENZ H
 P"/AU OR "LENZ H W"/AU)
 E LENZ HOLGER/AU

L25 6 SEA ABB=ON PLU=ON "LENZ HOLGER"/AU
 E MUNDT C/AU

L26 82 SEA ABB=ON PLU=ON ("MUNDT C"/AU OR "MUNDT C A M"/AU OR
 "MUNDT C C"/AU OR "MUNDT C S"/AU OR "MUNDT CLAUDIA"/AU)
 E SCHMIDT M/AU

L27 1651 SEA ABB=ON PLU=ON ("SCHMIDT M"/AU OR "SCHMIDT M A"/AU OR
 "SCHMIDT M A E"/AU OR "SCHMIDT M ALEXANDER"/AU OR "SCHMIDT M
 ALEXANDR"/AU OR "SCHMIDT M B"/AU OR "SCHMIDT M BRUDEL M"/AU OR
 "SCHMIDT M C"/AU OR "SCHMIDT M CHRISTIANE"/AU OR "SCHMIDT M
 E"/AU OR "SCHMIDT M ERNEST"/AU OR "SCHMIDT M F"/AU OR "SCHMIDT
 M F G"/AU OR "SCHMIDT M G"/AU OR "SCHMIDT M H"/AU OR "SCHMIDT
 M J"/AU OR "SCHMIDT M J G"/AU OR "SCHMIDT M J J"/AU OR
 "SCHMIDT M J M"/AU OR "SCHMIDT M K"/AU OR "SCHMIDT M L"/AU OR
 "SCHMIDT M LUISE"/AU OR "SCHMIDT M O"/AU OR "SCHMIDT M P"/AU
 OR "SCHMIDT M R"/AU OR "SCHMIDT M S"/AU OR "SCHMIDT M T"/AU OR
 "SCHMIDT M U"/AU OR "SCHMIDT M V"/AU OR "SCHMIDT M W"/AU OR
 "SCHMIDT M W I"/AU)
 E SCHMIDT MELANIE/AU

L28 17 SEA ABB=ON PLU=ON "SCHMIDT MELANIE"/AU
 E SCHREINER V/AU

L29 71 SEA ABB=ON PLU=ON ("SCHREINER V"/AU OR "SCHREINER V J"/AU OR
 "SCHREINER VOLKER"/AU)
 E SCHONROCK U/AU

L30 10 SEA ABB=ON PLU=ON ("SCHONROCK U"/AU OR "SCHONROCK UWE"/AU)
 E STAB F/AU

L31 6 SEA ABB=ON PLU=ON ("STAB F"/AU OR "STAB FRANZ"/AU)
 L32 QUE ABB=ON PLU=ON PY<=2001 OR AY<=2001 OR PRY<=2001 OR
 PD<20010725 OR AD<20010725 OR PRD<20010725
 E COOPERATIVE PHENOMENA/CT
 E E3+ALL

L33 8257 SEA ABB=ON PLU=ON COOPERATIVE PHENOMENA+NT/CT
 L34 4540 SEA ABB=ON PLU=ON (L14 OR L15 OR L16) AND (L17 OR L18 OR
 L19)

L35 5 SEA ABB=ON PLU=ON L34 AND (L21 OR L22 OR L23 OR L24 OR L25
 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31)

L36 5 SEA ABB=ON PLU=ON L35 AND L20
 L37 5 SEA ABB=ON PLU=ON (L35 OR L36)
 L38 4535 SEA ABB=ON PLU=ON L34 NOT L37
 L39 4179 SEA ABB=ON PLU=ON L38 AND L32

L40 2 SEA ABB=ON PLU=ON L39 AND L33
 E COMPOSITION/CT
 E E3+ALL
 L41 25708 SEA ABB=ON PLU=ON COMPOSITION+OLD,NT/CT
 L42 5 SEA ABB=ON PLU=ON L41 AND L39
 L43 439 SEA ABB=ON PLU=ON L39 AND COMPOSIT?
 L44 20 SEA ABB=ON PLU=ON L39 AND (COMPOSIT? AND COMBIN?)
 D SCA
 L45 1 SEA ABB=ON PLU=ON L44 AND FLAVOR/TI
 L46 QUE ABB=ON PLU=ON DRUG DELIVERY SYSTEMS+OLD,NT/CT
 L47 16 SEA ABB=ON PLU=ON L46 AND L39
 SEL AN 2
 L48 1 SEA ABB=ON PLU=ON ("139:47199"/AN OR "2003:472381"/AN) AND
 L47
 E COMBIN/CT
 E E7+ALL
 E E2+ALL
 L49 5317 SEA ABB=ON PLU=ON COMBINATION CHEMOTHERAPY/CT
 L50 0 SEA ABB=ON PLU=ON L49 AND L39
 L51 165 SEA ABB=ON PLU=ON L39 AND COMBIN?
 L52 2111 SEA ABB=ON PLU=ON (L14 OR L15 OR L16) (L) (COADMIN? OR
 COMBIN? OR COTHERAP?)
 L53 1273 SEA ABB=ON PLU=ON (L17 OR L18 OR L19) (L) (COADMIN? OR
 COMBIN? OR COTHERAP?)
 L54 140 SEA ABB=ON PLU=ON L52 AND L53
 L55 6 SEA ABB=ON PLU=ON L54 AND (L20 OR L21 OR L22 OR L23 OR L24
 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31)
 L56 134 SEA ABB=ON PLU=ON L54 NOT L55
 L57 112 SEA ABB=ON PLU=ON L56 AND L32
 L58 8 SEA ABB=ON PLU=ON L57 AND P/DT
 SEL AN L58 1
 L59 1 SEA ABB=ON PLU=ON ("138:44726"/AN OR "2002:977644"/AN) AND
 L58
 L60 104 SEA ABB=ON PLU=ON L57 NOT L58
 SEL AN L60 5 41 86
 L61 3 SEA ABB=ON PLU=ON ("102:179792"/AN OR "134:128770"/AN OR
 "1933:53719"/AN OR "1985:179792"/AN OR "2000:838607"/AN OR
 "27:53719"/AN) AND L60
 SEL AN 2-3 L61
 L62 2 SEA ABB=ON PLU=ON ("102:179792"/AN OR "1933:53719"/AN OR
 "1985:179792"/AN OR "27:53719"/AN) AND L61
 L63 3 SEA ABB=ON PLU=ON L59 OR L62
 L64 6 SEA ABB=ON PLU=ON L37 OR L55

FILE 'MEDLINE' ENTERED AT 12:51:59 ON 19 MAY 2005

L65 59230 SEA ABB=ON PLU=ON CREATININE+NT/CT OR L14 OR L15
 L66 35999 SEA ABB=ON PLU=ON L17 OR L18 OR CREATINE+NT/CT
 L67 3956 SEA ABB=ON PLU=ON L65/MAJ
 L68 9764 SEA ABB=ON PLU=ON L66/MAJ
 L69 43 SEA ABB=ON PLU=ON L67 (L) AD/CT
 L70 303 SEA ABB=ON PLU=ON L68 (L) AD/CT
 L71 5 SEA ABB=ON PLU=ON L69 AND L70
 D TRI TOT
 D AB 1-3 5
 L72 43 SEA ABB=ON PLU=ON L69 AND (L14 OR L15)
 L73 282 SEA ABB=ON PLU=ON L70 AND (L17 OR L18)
 L74 4 SEA ABB=ON PLU=ON L72 AND L73
 D TRI TOT
 D AB TOT
 SEL AN 3-4 L74
 L75 2 SEA ABB=ON PLU=ON (80013280/AN OR 88012290/AN) AND L74
 D SCA
 D BIB TOT
 SEL AN 1 L75
 L76 1 SEA ABB=ON PLU=ON 88012290/AN AND L75

FILE 'EMBASE' ENTERED AT 13:05:22 ON 19 MAY 2005

L77 52365 SEA ABB=ON PLU=ON (L14 OR L15)
 E CREATININE/CT
 E E3+ALL

L78 24345 SEA ABB=ON PLU=ON CREATININE/CT

L79 29680 SEA ABB=ON PLU=ON (L17 OR L18)
 E CREATINE/CT
 E E3+ALL

L80 3359 SEA ABB=ON PLU=ON CREATINE/CT

L81 2654 SEA ABB=ON PLU=ON (L77 OR L78) AND (L79 OR L80)

L82 17 SEA ABB=ON PLU=ON L78 (L) CB/CT

L83 27 SEA ABB=ON PLU=ON L80 (L) CB/CT

L84 1 SEA ABB=ON PLU=ON L82 AND L83

L85 3236 SEA ABB=ON PLU=ON L77 (L) (COADMIN? OR COTHERAP? OR COMBIN?)

L86 17 SEA ABB=ON PLU=ON L78 (L) (COADMIN? OR COTHERAP? OR COMBIN?)

L87 17 SEA ABB=ON PLU=ON L85 AND L86

L88 9 SEA ABB=ON PLU=ON L87 AND PY<=2001

FILE 'BIOSIS' ENTERED AT 13:12:33 ON 19 MAY 2005

L89 2737 SEA ABB=ON PLU=ON (L14 OR L15) AND (L17 OR L18)

L90 150 SEA ABB=ON PLU=ON L89 AND (COADMIN? OR COTHERAP? OR COMBIN?)
 E BIERGIESSER H/AU
 E BLATT T/AU

L91 13 SEA ABB=ON PLU=ON ("BLATT T"/AU OR "BLATT THOMAS"/AU)
 E KRUSE I/AU

L92 15 SEA ABB=ON PLU=ON ("KRUSE I"/AU OR "KRUSE I M"/AU)
 E LENZ H/AU

L93 223 SEA ABB=ON PLU=ON ("LENZ H"/AU OR "LENZ H J"/AU OR "LENZ H
 JUERGEN"/AU OR "LENZ H JURGEN"/AU OR "LENZ H L"/AU OR "LENZ H
 M"/AU OR "LENZ H R"/AU OR "LENZ HOLGER"/AU)
 E MUNDT C/AU

L94 128 SEA ABB=ON PLU=ON ("MUNDT C"/AU OR "MUNDT C A"/AU OR "MUNDT
 C C"/AU OR "MUNDT C H"/AU OR "MUNDT C J"/AU OR "MUNDT C M"/AU
 OR "MUNDT C S"/AU OR "MUNDT CLAUDIA"/AU)
 E SCHREINER M/AU

L95 75 SEA ABB=ON PLU=ON ("SCHREINER M"/AU OR "SCHREINER M E"/AU OR
 "SCHREINER M L"/AU OR "SCHREINER M S"/AU)
 E SCHREINER V/AU

L96 47 SEA ABB=ON PLU=ON ("SCHREINER V"/AU OR "SCHREINER V J"/AU OR
 "SCHREINER VOLKER"/AU)
 E SCROROCK U/AU
 E SCHONROCK U/AU

L97 5 SEA ABB=ON PLU=ON ("SCHONROCK U"/AU OR "SCHONROCK UWE"/AU)
 E STAB F/AU

L98 14 SEA ABB=ON PLU=ON ("STAB F"/AU OR "STAB FRANZ"/AU)

L99 337 SEA ABB=ON PLU=ON BEIERSDORF/CS

L100 0 SEA ABB=ON PLU=ON L90 AND (L91 OR L92 OR L93 OR L94 OR L95
 OR L96 OR L97 OR L98 OR L99)

L101 1 SEA ABB=ON PLU=ON L89 AND (L91 OR L92 OR L93 OR L94 OR L95
 OR L96 OR L97 OR L98 OR L99)

FILE 'WPIX' ENTERED AT 13:18:49 ON 19 MAY 2005

E CREATININE/DRN
 E E3+ALL

L102 513 SEA ABB=ON PLU=ON 0203/DRN OR R00203/DCN
 E CREATININE/CN

L103 8 SEA ABB=ON PLU=ON (CREATININE/CN OR "CREATININE ACETATE"/CN
 OR "CREATININE FORMATE"/CN OR "CREATININE HDROCHLORIDE"/CN OR
 "CREATININE HYDROBROMIDE"/CN OR CREATININE-AMIDOHYDROLASE/CN
 OR CREATININE-DEAMINASE/CN OR CREATININE-DEIMINASE/CN OR
 CREATININE-IMINOHYDROLASE/CN OR CREATININE-SULFATE-SEROTONIN/CN
)
 D QUE L14

L104 1226 SEA ABB=ON PLU=ON (IMIDAZOL? (1A) ONE (4A)AMINO (2A)
 (DIHYDRO OR DI (1A) HYDRO?) (1A) METHYL OR IMIDAZOL? (3A)
 (IMINO OR AMINO) (1A) METHYL OR IMIDAZOL? (1A) OL (1A)AMINO

(5A) METHYL OR CREATININE OR METHYLGLYCOCYAMIDINE OR METHYL
(1A) (GLYCOAMIDINE OR GLYCO? (1A) AMIDINE))/BIX
D QUE L15

L105 3 SEA ABB=ON PLU=ON ((METHYLHYDANTOIN? OR METHYL(1A) HYDANTION?
) (1A) IMIDE OR AMINO (1A) (METHYLIMIDAZOLIN?(1A) ONE OR
METHYL (2A) (DIHYDROIMIDAZOL? (1A) ONE OR (DIHYDRO OR DI (1A)
HYDRO?) (1A)IMIDAZOL?)) (1A) ONE OR NSC13123 OR NSC(1A) (13123
OR 13 (1A) 123) OR TEGO? (1A) COSMO?)/BIX
E CREATINE/DRN
E E3+ALL

L106 412 SEA ABB=ON PLU=ON R00118/DCN OR 0118/DRN
E CREATINE/CN

L107 33 SEA ABB=ON PLU=ON (CREATINE/CN OR "CREATINE ACETATE"/CN OR
"CREATINE ALEURATE"/CN OR "CREATINE ALPHA-KETOGLUTARATE"/CN OR
"CREATINE AMIDINOHYDROLASE"/CN OR "CREATINE ASCORBATE"/CN OR
"CREATINE ASPARTATE"/CN OR "CREATINE CITRATE"/CN OR "CREATINE
DIHYDRO-OROTATE"/CN OR "CREATINE DIHYDROOROTATE"/CN OR
"CREATINE FUMARATE"/CN OR "CREATINE FYTATE"/CN OR "CREATINE
GLYCOLATE"/CN OR "CREATINE HYDROCHLORIDE"/CN OR "CREATINE
KINASE CONVERSION FACTOR"/CN OR "CREATINE MALATE"/CN OR
"CREATINE MALEATE"/CN OR "CREATINE MANDELATE"/CN OR "CREATINE
MONOHYDRATE"/CN OR "CREATINE OROTATE"/CN OR "CREATINE PHOSPHATE
"/CN OR "CREATINE PHYTATE"/CN OR "CREATINE PYRUVATE"/CN OR
"CREATINE PYRUVATE MONOHYDRATE"/CN OR "CREATINE SALICYLATE"/CN
OR "CREATINE SULFATE"/CN OR CREATINE-ACETATE/CN OR CREATINE-ALE
URATE/CN OR CREATINE-ALPHA-KETOGLUTARATE/CN OR CREATINE-ASPARTA
TE/CN OR CREATINE-CITRATE/CN OR CREATINE-DIHYDROLIPOATE/CN OR
CREATINE-FOLATE/CN OR CREATINE-FORMATE/CN OR CREATINE-FUMARATE/
CN OR CREATINE-FYTATE/CN OR CREATINE-GLUCONATE/CN OR CREATINE-G
LYCOLATE/CN OR CREATINE-HYDROCHLORIDE/CN OR CREATINE-KINASE/CN
OR CREATINE-KINASE-CONVERSION-FACTOR/CN OR CREATINE-LIPOATE/CN
OR CREATINE-MANDELATE/CN OR CREATINE-PHOSPHATE/CN OR CREATINE-P
HOSPHOENOLPYRUVATE/CN OR CREATINE-PHYTATE/CN OR CREATINE-SALICY
LATE/CN OR CREATINE-SULFATE/CN)
D QUE L17

L108 1269 SEA ABB=ON PLU=ON (GLYCINE (2A) (AMINOIMINOMETHYL OR AMINO
(1A) (IMINOMETHYL OR IMINO (1A) METHYL)) (2A)METHYL OR
CREATINE OR COSMOCAIR? OR METHYLGUANIDOACETIC (1A) ACID OR
METHYLGUANIDO (1A) ACETIC (1A) ACID OR METHYL (2A) (GUANYLGLYCIN
E OR GUANYL (1A) GLYCINE))/BIX
D QUE L18

L109 108 SEA ABB=ON PLU=ON (NSC8752 OR NSC (1A) 8752 OR PHOSPHAGEN?)/B
IX

L110 300 SEA ABB=ON PLU=ON (L102 OR L103 OR L104 OR L105) AND (L106
OR L107 OR L108 OR L109)

L111 1869 SEA ABB=ON PLU=ON BEIERSDORF/CS, PA
E BIERGIESSER H/AU

L112 29 SEA ABB=ON PLU=ON "BIERGIESSER H"/AU
E BLATT T/AU

L113 48 SEA ABB=ON PLU=ON "BLATT T"/AU
E KRUSE I/AU

L114 22 SEA ABB=ON PLU=ON ("KRUSE I"/AU OR "KRUSE I M"/AU)
E LENZ H/AU

L115 142 SEA ABB=ON PLU=ON ("LENZ H"/AU OR "LENZ H E"/AU OR "LENZ H
G"/AU OR "LENZ H H"/AU OR "LENZ H J"/AU OR "LENZ H N"/AU OR
"LENZ H P"/AU OR "LENZ H R"/AU OR "LENZ H U"/AU)
E MUNDT C/AU

L116 70 SEA ABB=ON PLU=ON ("MUNDT C"/AU OR "MUNDT C A"/AU OR "MUNDT
C W"/AU)
E SCHMIDT M/AU

L117 1406 SEA ABB=ON PLU=ON ("SCHMIDT M"/AU OR "SCHMIDT M A"/AU OR
"SCHMIDT M B"/AU OR "SCHMIDT M C"/AU OR "SCHMIDT M D"/AU OR
"SCHMIDT M D I"/AU OR "SCHMIDT M E"/AU OR "SCHMIDT M F"/AU OR
"SCHMIDT M F G"/AU OR "SCHMIDT M G"/AU OR "SCHMIDT M H"/AU OR
"SCHMIDT M J"/AU OR "SCHMIDT M L"/AU OR "SCHMIDT M N"/AU OR
"SCHMIDT M O"/AU OR "SCHMIDT M P"/AU OR "SCHMIDT M R"/AU OR

```

"SCHMIDT M S"/AU OR "SCHMIDT M T"/AU OR "SCHMIDT M U"/AU OR
"SCHMIDT M W"/AU OR "SCHMIDT M Z"/AU)
E SCHREINER V/AU
L118      66 SEA ABB=ON  PLU=ON  "SCHREINER V"/AU
E SCHONROCK U/AU
L119      13 SEA ABB=ON  PLU=ON  "SCHONROCK U"/AU
E STAB F/AU
L120      21 SEA ABB=ON  PLU=ON  "STAB F"/AU
L121      14 SEA ABB=ON  PLU=ON  L110 AND (L111 OR L112 OR L113 OR L114 OR
L115 OR L116 OR L117 OR L118 OR L119 OR L120)
L122      286 SEA ABB=ON  PLU=ON  L110 NOT L121
L123      191 SEA ABB=ON  PLU=ON  L122 NOT (PY>2001 OR AY>2001 OR PRY>2001)
L124      44 SEA ABB=ON  PLU=ON  L123 AND (COMBIN? OR COTHERAP? OR COADMIN?
OR COMPOSIT?)/BIX

```

FILE 'MEDLINE' ENTERED AT 13:34:29 ON 19 MAY 2005

```

L125      3279 SEA ABB=ON  PLU=ON  L65 AND L66
L126      222 SEA ABB=ON  PLU=ON  L125 AND (COMBIN? OR COTHERAP? OR COADMIN?
OR COMPOSIT? OR COMBN?)
L127      187 SEA ABB=ON  PLU=ON  L126 AND PY<=2001
L128      127 SEA ABB=ON  PLU=ON  L67 AND L68
L129      4 SEA ABB=ON  PLU=ON  L128 AND (COMBIN? OR COTHERAP? OR COADMIN?
OR COMPOSIT? OR COMBN?)
SEL AN L129 1
L130      1 SEA ABB=ON  PLU=ON  2000330694/AN AND L129
L131      183 SEA ABB=ON  PLU=ON  L127 NOT L128
E DRUG THERAPY/CT
E E6+ALL
L132      85624 SEA ABB=ON  PLU=ON  DRUG THERAPY, COMBINATION+NT/CT
E DRUG COMBIN/CT
E E6+ALL
L133      39511 SEA ABB=ON  PLU=ON  DRUG COMBINATIONS/CT
L134      40 SEA ABB=ON  PLU=ON  L125 AND (L132 OR L133)

```

=> b. hcap

FILE 'HCAPLUS' ENTERED AT 13:53:48 ON 19 MAY 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 May 2005 VOL 142 ISS 21

FILE LAST UPDATED: 18 May 2005 (20050518/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all l64 fhitr tot

```

L64 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:872669 HCAPLUS
DN 141:319574
ED Entered STN: 21 Oct 2004

```

Search done by Noble Jarrell

TI Cosmetic or dermatological preparations containing a combination of creatinine, creatine, and bioquinones

IN Schoenrock, Uwe; Schreiner, Volker; Staeb, Franz; Kruse, Inge; Biergiesser, Helga; Lenz, Holger; Mundt, Claudia; Schmidt, Melanie; Blatt, Thomas

PA Beiersdorf A.-G., Germany

SO PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DT Patent

LA German

IC ICM A61K007-48

ICS A61K007-06; A61K007-42; A61P017-00

CC 62-4 (Essential Oils and Cosmetics)

Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004089326	A1	20041021	WO 2004-EP50482	20040407
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10316666	A1	20041028	DE 2003-10316666	20030410
PRAI	DE 2003-10316666	A	20030410		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004089326	ICM	A61K007-48
	ICS	A61K007-06; A61K007-42; A61P017-00
WO 2004089326	ECLA	A61K008/35C; A61K008/64; A61Q001/02; A61Q017/04; A61Q019/00
DE 10316666	ECLA	A61K008/35C; A61K008/64; A61Q001/02; A61Q017/04; A61Q019/00

AB The invention relates to cosmetic or dermatol. prepsns. containing a combination of active ingredients made from creatinine and/or derivs. thereof containing creatine and/or derivs. thereof and bioquinones, in addition to exts. from plant and animal. Thus a PIT emulsion contained (weight/weight%): glycerin monostearate 0.50; polyoxyethylene (30) cetylstearyl ether 5.00; cetyl alc. 2.50; diethylhexyl butamidotriazone 1.00; ethylhexyl triazone 4.00; phenylbenzimidazole sulfonic acid 0.50; titanium dioxide 0.50; zinc oxide 2.00; butylene glycol dicaprylate/dicaprate 5.00; phenylmethylpolysiloxane 2.00; PVP-hexadecene copolymer 0.50; glycerin 3.00; tocopherol acetate 0.50; creatine 1.00; creatinine 0.30; Ubiquinone (Q10) 0.04; α -glucosylrutin 0.10; ethanol 3.00; preservative, perfume q.s.; water to 100.

ST creatinine creatine bioquinone ubiquinone cosmetics skin hair

IT Skin, disease

(aging; cosmetic or dermatol. prepsns. containing a combination of creatinine, creatine, and bioquinones)

IT Dermatitis

(atopic; cosmetic or dermatol. prepsns. containing a combination of creatinine, creatine, and bioquinones)

IT Quinones

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)

(bioquinones; cosmetic or dermatol. prepsns. containing a combination of creatinine, creatine, and bioquinones)

IT Acne
(comedo; cosmetic or dermatol. preps. containing a combination of creatinine, creatine, and bioquinones)

IT Hair
Pruritus
Psoriasis
Seborrhea
Skin, disease
Sunscreens
Vitiligo
Wound healing
(cosmetic or dermatol. preps. containing a combination of creatinine, creatine, and bioquinones)

IT Cosmetics
(creams; cosmetic or dermatol. preps. containing a combination of creatinine, creatine, and bioquinones)

IT Skin, disease
(depigmentation; cosmetic or dermatol. preps. containing a combination of creatinine, creatine, and bioquinones)

IT Ceramides
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(disorders in biosynthesis of; cosmetic or dermatol. preps. containing a combination of creatinine, creatine, and bioquinones)

IT Collagens, biological studies
Elastins
Glycosaminoglycans, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(disorders in homeostasis of; cosmetic or dermatol. preps. containing a combination of creatinine, creatine, and bioquinones)

IT DNA
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(disorders in synthesis of; cosmetic or dermatol. preps. containing a combination of creatinine, creatine, and bioquinones)

IT Skin, disease
(dry; cosmetic or dermatol. preps. containing a combination of creatinine, creatine, and bioquinones)

IT Cosmetics
(emulsions; cosmetic or dermatol. preps. containing a combination of creatinine, creatine, and bioquinones)

IT Animal
Embryophyta
(exts. from; cosmetic or dermatol. preps. containing a combination of creatinine, creatine, and bioquinones)

IT Skin, disease
(light dermatosis; cosmetic or dermatol. preps. containing a combination of creatinine, creatine, and bioquinones)

IT Immunosuppression
(light-induced; cosmetic or dermatol. preps. containing a combination of creatinine, creatine, and bioquinones)

IT Skin, disease
(pigmentation; cosmetic or dermatol. preps. containing a combination of creatinine, creatine, and bioquinones)

IT 57-00-1, Creatine 60-27-5, Creatinine
303-98-0, Coenzyme Q10 130603-71-3, α -Glucosylrutin
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(cosmetic or dermatol. preps. containing a combination of creatinine, creatine, and bioquinones)

IT 9004-61-9, Hyaluronic acid
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(disorders in homeostasis of; cosmetic or dermatol. preps. containing a combination of creatinine, creatine, and bioquinones)

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE


- (1) Anon; PATENT ABSTRACTS OF JAPAN 2001, V2000(21)
- (2) Avicena Group Inc; WO 0100203 A 2001 HCAPLUS
- (3) Beiersdorf Ag; WO 0202075 A 2002 HCAPLUS
- (4) Biergiesser, H; WO 03005988 A 2003
- (5) Biergiesser, H; WO 03011241 A 2003 HCAPLUS
- (6) Goldschmidt Ag Th; DE 10119608 A 2002 HCAPLUS
- (7) Grasser, B; WO 02076408 A 2002
- (8) Hamilton, N; WO 0211717 A 2002 HCAPLUS
- (9) Howard Foundation; WO 02069740 A 2002 HCAPLUS
- (10) Lion Corp; JP 2001114701 A 2001 HCAPLUS
- (11) Rizzo, A; EP 0565010 A 1993 HCAPLUS
- (12) Shaath, N; SOAP & COSMETICS 2002, V78(8), P39 HCAPLUS

IT 57-00-1, Creatine

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(cosmetic or dermatol. preps. containing a combination of creatinine, creatine, and bioquinones)

RN 57-00-1 HCAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



L64 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:695232 HCAPLUS

DN 141:212359

ED Entered STN: 26 Aug 2004

TI Cosmetic and/or dermatological preparations containing
8-hexadecene-1,16-dicarboxylic acid

IN Max, Heiner; Doering, Thomas; Wolber, Rainer; Blatt, Thomas;
Kolbe, Ludger; Mundt, Claudia; Gallinat, Stefan

PA Beiersdorf A.-G., Germany

SO Ger. Offen., 40 pp.

CODEN: GWXXBX

DT Patent

LA German

IC ICM A61K007-00

ICS A61K007-06; A61K007-48; A61K007-50

CC 62-4 (Essential Oils and Cosmetics)

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10305965	A1	20040826	DE 2003-10305965	20030212
PRAI DE 2003-10305965		20030212		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
DE 10305965	ICM	A61K007-00
	ICS	A61K007-06; A61K007-48; A61K007-50

AB The invention concerns cosmetic and/or dermatol. preps. containing 8-hexadecene-1,16-dicarboxylic acid at a concentration of 0.005-20 weight/weight%. 8-Hexadecene-1,16-dicarboxylic acid can be combined with creatine, creatinine, soybean germ exts., isoflavone-150, acetylcarnitine or carnitine. The preps. contribute to skin revitalization. Thus a formulation contained (weight/weight%): glycerin monostearate 0.50; polyoxyethylene(30)cetylstearylether 5.00; cetyl alc. 2.50; diethylhexyl butamidotriazone 1.00; ethylhexyl triazone 4.00; phenylbenzimidazole sulfonic acid 0.50; titanium dioxide 0.50; zinc oxide

2.00; butylene glycol dicaprylate/dicaprate 5.00; phenylmethylpolysiloxane 2.00; PVP-hexadecene copolymer 0.50; glycerin 3.00; tocopherol acetate 0.50; 8-hexadecene-1,16-dicarboxylic acid 1.00; isoflavone-150 0.30; alpha-glucosylrutin 0.10; preservative q.s.; ethanol 3.00; perfume q.s.; water to 100.

ST cosmetic cream emulsion octadecenedioic acid
 IT Skin, disease
 (aging; cosmetic and/or dermatol. prepns. containing 8-hexadecene-1,16-dicarboxylic acid)
 IT Wound healing
 (cosmetic and/or dermatol. prepns. containing 8-hexadecene-1,16-dicarboxylic acid)
 IT Cosmetics
 (creams; cosmetic and/or dermatol. prepns. containing 8-hexadecene-1,16-dicarboxylic acid)
 IT Cosmetics
 (emulsions; cosmetic and/or dermatol. prepns. containing 8-hexadecene-1,16-dicarboxylic acid)
 IT Cosmetics
 (gels; cosmetic and/or dermatol. prepns. containing 8-hexadecene-1,16-dicarboxylic acid)
 IT 57-00-1, Creatine 60-27-5, Creatinine
 541-15-1, Carnitine 3040-38-8, Acetylcarnitine 20701-68-2
 744245-35-0, Isoflavone 150
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
 (cosmetic and/or dermatol. prepns. containing 8-hexadecene-1,16-dicarboxylic acid)


RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE

- (1) Anon; EP 0662946 B2 HCAPLUS
- (2) Anon; DE 10150731 A1 HCAPLUS
- (3) Anon; DE 10150732 A1 HCAPLUS
- (4) Anon; DE 10150734 A1 HCAPLUS
- (5) Anon; DE 10150735 A1 HCAPLUS
- (6) Anon; DE 10150742 A1 HCAPLUS
- (7) Anon; DE 10155959 A1 HCAPLUS
- (8) Anon; DE 10155961 A1 HCAPLUS
- (9) Anon; DE 10163786 A1 HCAPLUS
- (10) Anon; DE 10213957 A1 HCAPLUS
- (11) Anon; DE 10249367 A1 HCAPLUS
- (12) Anon; US 5545399 A HCAPLUS
- (13) Anon; WO 9407462 A1 HCAPLUS
- (14) Anon; WO 9407837 A1 HCAPLUS

IT 57-00-1, Creatine
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
 (cosmetic and/or dermatol. prepns. containing 8-hexadecene-1,16-dicarboxylic acid)

RN 57-00-1 HCAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



L64 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:605428 HCAPLUS

DN 141:145361

ED Entered STN: 29 Jul 2004

TI Cosmetic and dermatological preparations containing creatine and creatinine and/or their derivatives in combination with soybean germ extracts

IN Staeb, Franz; Blatt, Thomas; Schmidt, Melanie;
 Mundt, Claudia; Gallinat, Stefan; Venzke, Kirsten; Lenz,

Holger; Meier, Zimmerer Cornelia
 PA Beiersdorf Ag, Germany
 SO Ger. Offen., 17 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 IC ICM A61K007-48
 ICS A61K007-40
 CC 62-4 (Essential Oils and Cosmetics)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10301632	A1	20040729	DE 2003-10301632	20030117
	WO 2004064801	A1	20040805	WO 2004-EP50015	20040114
W:	AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ				
PRAI	DE 2003-10301632	A	20030117		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
DE 10301632	ICM	A61K007-48
	ICS	A61K007-40
DE 10301632	ECLA	A61K008/44; A61K008/49F1; A61K008/97; A61Q007/00; A61Q017/04; A61Q019/08
WO 2004064801	ECLA	A61K008/44; A61K008/49F1; A61K008/97; A61Q007/00; A61Q017/04; A61Q019/08

AB The invention concerns cosmetic and dermatol. preps. containing
 creatine, creatinine, and/or their derivs. in
 combination with soybean germ exts. Exts. contain daidzin,
 glycitin, genistin, daidzein, glycitein, genistein, and saponins. The
 compns. are used to reconstruct and rejuvenate skin and promote wound
 healing. Thus an O/W cream contained (weight/weight%): glycerin monostearate
 0.50, PEG-30-cetylstearyl ether 5.00, cetyl alc. 2.50,
 diethylhexylbutamidotriazone 1.00, ethylhexyltriazone 4.00,
 phenylbenzimidazolesulfonic acid 0.50, titanium dioxide 0.50, zinc oxide
 2.00, butylene glycol dicaprylate/dicaprate 5.00, phenylmethyl siloxane
 2.00, PVP-hexadecene copolymer 0.50, glycerin 3.00, tocopheryl acetate
 0.50, Isoflavone-150 0.10, creatinine 0.30, creatine
 0.30, α -glucosylrutin 0.10, preservative qs, ethanol 3.00, perfume
 qs, and water to 100.

ST cosmetic soybean germ creatine creatinine; isoflavone
 cosmetic soybean germ

IT Skin, disease
 (aging; cosmetic and dermatol. preps. containing creatine and
 creatinine, and/or their derivs. in combination with
 soybean germ exts.)

IT Wound healing
 (cosmetic and dermatol. preps. containing creatine and
 creatinine, and/or their derivs. in combination with
 soybean germ exts.)

IT Saponins
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
 (cosmetic and dermatol. preps. containing creatine and
 creatinine, and/or their derivs. in combination with
 soybean germ exts.)

IT Cosmetics
 (creams; cosmetic and dermatol. preps. containing creatine and
 creatinine, and/or their derivs. in combination with
 soybean germ exts.)

IT Cosmetics
 (emulsions; cosmetic and dermatol. preps. containing creatine

and creatinine, and/or their derivs. in combination with soybean germ exts.)

IT Glycine max
(germ, extract of; cosmetic and dermatol. preps. containing creatine and creatinine, and/or their derivs. in combination with soybean germ exts.)


IT 60-27-5D, Creatinine, derivs.
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(cosmetic and dermatol. preps. containing creatine and creatinine and/or their derivs. in combination with soybean germ exts.)

IT 57-00-1, Creatine 57-00-1D, Creatine
, derivs. 446-72-0 486-66-8, Daidzein 529-59-9, Genistin 552-66-9,
Daidzin 40246-10-4, Glycitin 40957-83-3, Glycitein
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(cosmetic and dermatol. preps. containing creatine and creatinine, and/or their derivs. in combination with soybean germ exts.)

IT 60-27-5D, Creatinine, derivs.
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(cosmetic and dermatol. preps. containing creatine and creatinine and/or their derivs. in combination with soybean germ exts.)

RN 60-27-5 HCAPLUS

CN 4H-Imidazol-4-one, 2-amino-1,5-dihydro-1-methyl- (9CI) (CA INDEX NAME)



L64 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:268294 HCAPLUS

DN 140:292228

ED Entered STN: 02 Apr 2004

TI Cosmetic skin care formulations containing a combination of creatine, creatinine, phenoxy ethanol and optionally glycerin

PA Beiersdorf A.-G., Germany

SO Ger. Gebrauchsmusterschrift, 27 pp.
CODEN: GGXXFR

DT Patent

LA German

IC ICM A61K007-40
ICS A61K007-48; A61K007-00

CC 62-4 (Essential Oils and Cosmetics)

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 20318413	U1	20040401	DE 2003-20318413	20031126
PRAI DE 2003-20318413		20031126		

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
DE 20318413	ICM	A61K007-40
	ICS	A61K007-48; A61K007-00
DE 20318413	ECLA	A61K008/34C; A61K008/34D; A61K008/44; A61Q017/00

AB The invention concerns skin care cosmetics that contain as active ingredients creatine, creatinine, phenoxy ethanol and optionally glycerin. Thus a composition included (weight/weight%): glyceryl stearate 2; shea butter 2; stearyl alc. 2; cetyl alc. 3; hydrogenated coco glycerides 2;


caprylic/capric triglyceride 1; ethylhexyl coco fatty acid ester 2; cyclomethicone 3; dicaprylyl ether 3; tocopheryl acetate 1; sodium ascorbyl phosphate 0.1; panthenol 1; ubiquinone Q10 0.03; retinyl palmitate 0.1; creatinine 0.08; creatine 1.0; phenoxyethanol 0.8; paraben 0.6; ethylhexylglycerin 1; carbomer 0.1; starch 0.5; glycerin 10; dyes 0.05; fillers and additives 0.2; perfume q.s.; water to 100.

ST creatine creatinine phenoxy ethanol glycerol skin cosmetics
IT Cosmetics
Skin
(cosmetic skin care formulations containing a combination of creatine, creatinine, phenoxy ethanol and optionally glycerin)

IT 56-81-5, Glycerin, biological studies 57-00-1, Creatine
60-27-5, Creatinine 122-99-6, Phenoxy ethanol
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(cosmetic skin care formulations containing a combination of creatine, creatinine, phenoxy ethanol and optionally glycerin)

IT 57-00-1, Creatine
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(cosmetic skin care formulations containing a combination of creatine, creatinine, phenoxy ethanol and optionally glycerin)

RN 57-00-1 HCAPLUS
CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



L64 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:117581 HCAPLUS
DN 138:158557
ED Entered STN: 14 Feb 2003
TI Cosmetic and dermatological preparations containing a combination of creatinine and creatine or their derivatives
IN Biergiesser, Helga; Blatt, Thomas; Kruse, Inge
; Lenz, Holger; Mundt, Claudia; Schmidt, Melanie; Schoenrock, Uwe; Schreiner, Volker; Staeb, Franz
PA Beiersdorf AG, Germany
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA German
IC ICM A61K007-48
ICS A61P017-00; A61P017-02; A61P017-02; A61P017-06; A61P017-14;
A61P017-16
CC 62-4 (Essential Oils and Cosmetics)
Section cross-reference(s): 63
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003011242	A1	20030213	WO 2002-EP8125	20020722
W: JP, US				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
DE 10136077	A1	20030213	DE 2001-10136077	20010725
EP 1414402	A1	20040506	EP 2002-764746	20020722
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005503373	T2	20050203	JP 2003-516474	20020722
US 2004241197	A1	20041202	US 2004-767962	20040126
PRAI DE 2001-10136077	A	20010725		

WO 2002-EP8124 A1 20020722
 WO 2002-EP8125 W 20020722

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003011242	ICM	A61K007-48
	ICS	A61P017-00; A61P017-02; A61P017-02; A61P017-06; A61P017-14; A61P017-16
DE 10136077	ECLA	A61K008/43; A61Q017/00; A61Q019/00; A61Q019/08
JP 2005503373	FTERM	4C083/AA122; 4C083/AB032; 4C083/AB212; 4C083/AB242; 4C083/AB342; 4C083/AB362; 4C083/AC012; 4C083/AC072; 4C083/AC092; 4C083/AC102; 4C083/AC122; 4C083/AC172; 4C083/AC182; 4C083/AC212; 4C083/AC242; 4C083/AC342; 4C083/AC352; 4C083/AC392; 4C083/AC402; 4C083/AC422; 4C083/AC442; 4C083/AC512; 4C083/AC532; 4C083/AC582; 4C083/AC741; 4C083/AC742; 4C083/AC851; 4C083/AC852; 4C083/AC862; 4C083/AD072; 4C083/AD092; 4C083/AD152; 4C083/AD162; 4C083/AD172; 4C083/AD202; 4C083/AD352; 4C083/AD512; 4C083/AD532; 4C083/AD632; 4C083/AD662; 4C083/BB51; 4C083/CC01; 4C083/CC02; 4C083/CC04; 4C083/CC05; 4C083/DD08; 4C083/DD11; 4C083/DD23; 4C083/DD31; 4C083/DD39; 4C083/DD41; 4C083/EE12; 4C083/EE13; 4C086/AA01; 4C086/AA02; 4C086/BC09; 4C086/DA40; 4C086/MA01; 4C086/MA02; 4C086/MA04; 4C086/MA10; 4C086/MA13; 4C086/MA16; 4C086/MA22; 4C086/MA23; 4C086/MA28; 4C086/MA34; 4C086/MA63; 4C086/NA14; 4C086/ZA89; 4C086/ZB22; 4C086/ZC41; 4C206/AA01; 4C206/AA02; 4C206/HA32; 4C206/MA01; 4C206/MA02; 4C206/MA04; 4C206/MA14; 4C206/MA24; 4C206/MA33; 4C206/MA37; 4C206/MA42; 4C206/MA43; 4C206/MA48; 4C206/MA54; 4C206/MA83; 4C206/NA14; 4C206/ZA89; 4C206/ZB22; 4C206/ZC41
US 2004241197	NCL	424/401.000
	ECLA	A61K008/43; A61Q017/00; A61Q019/00; A61Q019/08
AB		The invention relates to cosmetic or dermatol. preps. containing a combination of active ingredients consisting of creatinine and creatine or their derivs. The preps. are used for the treatment and prevention of dry skin, wound healing, itching, skin aging etc. Thus a PIT emulsion contained (weight/weight%): glycerin monostearate self-emulsifying 0.5; polyoxyethylene(30) cetylstearylether 5; cetyl alc. 2.5; diethylhexyl butamidotriazone 1; ethylhexyl triazone 4; phenylbenzimidazole sulfonic acid 0.5; titanium oxide 0.5; zinc oxide 2; butylene glycol dicaprylate/dicaprate 5; phenylmethylpolysiloxane 2; PVP hexadecene copolymer 0.5; glycerin 3; tocopherol acetate 0.5; creatine 0.2; creatinine 0.2; α -glucosylrutin 0.1; preservative q.s.; ethanol 3; perfume q.s.; water to 100.
ST		creatinine creatine cosmetic dermatol skin
IT		Skin, disease (aging; cosmetic and dermatol. preps. containing a combination of creatinine and creatine or their derivs.)
IT		Dermatitis (atopic; cosmetic and dermatol. preps. containing a combination of creatinine and creatine or their derivs.)
IT		Pruritus Psoriasis Seborrhea Vitiligo Wound healing (cosmetic and dermatol. preps. containing a combination of creatinine and creatine or their derivs.)
IT		Cosmetics (creams; cosmetic and dermatol. preps. containing a combination of creatinine and creatine or their derivs.)
IT		Skin, disease (dry; cosmetic and dermatol. preps. containing a combination of creatinine and creatine or their derivs.)

IT Cosmetics
(emulsions; cosmetic and dermatol. preps. containing a combination of creatinine and creatine or their derivs.)

IT Cosmetics
(gels; cosmetic and dermatol. preps. containing a combination of creatinine and creatine or their derivs.)

IT Cosmetics
(hydrodispersions; cosmetic and dermatol. preps. containing a combination of creatinine and creatine or their derivs.)

IT Skin, disease
(light; cosmetic and dermatol. preps. containing a combination of creatinine and creatine or their derivs.)

IT Skin, disease
(pigmentation; cosmetic and dermatol. preps. containing a combination of creatinine and creatine or their derivs.)

IT Drug delivery systems
(topical; cosmetic and dermatol. preps. containing a combination of creatinine and creatine or their derivs.)


IT 57-00-1, Creatine 57-00-1D, Creatine, derivs. 60-27-5, Creatinine 60-27-5D, Creatinine, derivs.
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cosmetic and dermatol. preps. containing a combination of creatinine and creatine or their derivs.)

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

(1) Ajinomoto Co Inc; JP 63263060 A 1988 HCAPLUS
(2) Anon; PATENT ABSTRACTS OF JAPAN 1989, V013(069), PC-569
(3) Anon; PATENT ABSTRACTS OF JAPAN 2001, V2000(12)
(4) Burke, D; JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL APPLICATIONS 1999, V732(2), P479 HCAPLUS
(5) Charles, H; US 5968544 A 1999 HCAPLUS
(6) Grasser, B; WO 02076408 A 2002
(7) Heinz, K; WO 0059519 A 2000 HCAPLUS
(8) Heinz, K; DE 19963628 A 2001
(9) Howard Foundation; WO 02069740 A 2002 HCAPLUS
(10) Lion Corp; JP 2000247866 A 2000 HCAPLUS
(11) Sueddeutsche Kalkstickstoff; DE 19841385 A 2000 HCAPLUS

IT 57-00-1, Creatine
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cosmetic and dermatol. preps. containing a combination of creatinine and creatine or their derivs.)

RN 57-00-1 HCAPLUS
CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



L64 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:117580 HCAPLUS
DN 138:158556
ED Entered STN: 14 Feb 2003
TI Cosmetic and dermatological preparations containing creatinine and/or its derivatives
IN Biergiesser, Helga; Blatt, Thomas; Kruse, Inge
; Schmidt, Melanie; Schoenrock, Uwe; Staeb, Franz
PA Beiersdorf AG, Germany
SO PCT Int. Appl., 35 pp.

CODEN: PIXXD2
 DT Patent
 LA German
 IC ICM A61K007-48
 ICS A61P017-00; A61P017-02; A61P017-06; A61P017-14; A61P017-16
 CC 62-4 (Essential Oils and Cosmetics)
 Section cross-reference(s): 63

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003011241	A1	20030213	WO 2002-EP8124	20020722
	WO 2003011241	C1	20030320		
	W: JP, US				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
	DE 10136076	A1	20030213	DE 2001-10136076	20010725
	EP 1414401	A1	20040506	EP 2002-760258	20020722
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2004538299	T2	20041224	JP 2003-516473	20020722
	US 2004241197	A1	20041202	US 2004-767962	20040126
PRAI	DE 2001-10136076	A	20010725		
	DE 2001-10136077	A	20010725		
	WO 2002-EP8124	W	20020722		
	WO 2002-EP8125	A1	20020722		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003011241	ICM	A61K007-48
	ICS	A61P017-00; A61P017-02; A61P017-06; A61P017-14; A61P017-16
DE 10136076	ECLA	A61K008/43; A61Q017/00; A61Q019/00; A61Q019/08
JP 2004538299	FTERM	4C083/AB032; 4C083/AB212; 4C083/AB242; 4C083/AB342; 4C083/AB352; 4C083/AC012; 4C083/AC072; 4C083/AC092; 4C083/AC102; 4C083/AC122; 4C083/AC172; 4C083/AC182; 4C083/AC212; 4C083/AC242; 4C083/AC332; 4C083/AC342; 4C083/AC352; 4C083/AC392; 4C083/AC402; 4C083/AC422; 4C083/AC532; 4C083/AC581; 4C083/AC582; 4C083/AC851; 4C083/AC852; 4C083/AD072; 4C083/AD092; 4C083/AD152; 4C083/AD172; 4C083/AD352; 4C083/AD412; 4C083/AD532; 4C083/AD662; 4C083/BB41; 4C083/BB48; 4C083/CC04; 4C083/CC05; 4C083/DD27; 4C083/DD31; 4C083/DD32; 4C083/DD33; 4C083/DD34; 4C083/DD41; 4C083/EE12; 4C083/EE13; 4C083/EE22; 4C083/EE23; 4C086/AA01; 4C086/BC35; 4C086/MA02; 4C086/MA05; 4C086/MA17; 4C086/MA28; 4C086/MA63; 4C086/NA14; 4C086/ZA89; 4C086/ZA92; 4C086/ZC75; 4C206/AA01; 4C206/FA53; 4C206/MA02; 4C206/MA05; 4C206/MA37; 4C206/MA48; 4C206/MA83; 4C206/NA14; 4C206/ZA89; 4C206/ZA92; 4C206/ZC75
US 2004241197	NCL	424/401.000
	ECLA	A61K008/43; A61Q017/00; A61Q019/00; A61Q019/08

AB The invention relates to cosmetic or dermatol. preps. containing a combination of active ingredients consisting of creatinine and creatine or their derivs. The preps. are used for the treatment and prevention of dry skin, wound healing, itching, skin aging etc. Thus a PIT emulsion contained (weight/weight%): glycerin monostearate self-emulsifying 0.5; polyoxyethylene(30) cetylstearyl ether 5; cetyl alc. 2.5; diethylhexyl butamidotriazole 1; ethylhexyl triazole 4; phenylbenzimidazole sulfonic acid 0.5; titanium oxide 0.5; zinc oxide 2; butylene glycol dicaprylate/dicaprate 5; phenylmethylpolysiloxane 2; PVP hexadecene copolymer 0.5; glycerin 3; tocopherol acetate 0.5; creatine 0.2; creatinine 0.2; α -glucosylrutin 0.1; preservative q.s.; ethanol 3; perfume q.s.; water to 100.

ST creatinine creatine cosmetic dermatol skin

IT Skin, disease

(aging; cosmetic and dermatol. preps. containing creatinine and/or its derivs.)

IT Dermatitis
(atopic; cosmetic and dermatol. preps. containing creatinine and/or its derivs.)

IT Pruritus
Psoriasis
Seborrhea
Vitiligo
Wound healing
(cosmetic and dermatol. preps. containing creatinine and/or its derivs.)

IT Cosmetics
(creams; cosmetic and dermatol. preps. containing creatinine and/or its derivs.)

IT Skin, disease
(dry; cosmetic and dermatol. preps. containing creatinine and/or its derivs.)

IT Cosmetics
(emulsions; cosmetic and dermatol. preps. containing creatinine and/or its derivs.)

IT Cosmetics
(gels; cosmetic and dermatol. preps. containing creatinine and/or its derivs.)

IT Cosmetics
(hydrodispersions; cosmetic and dermatol. preps. containing creatinine and/or its derivs.)

IT Skin, disease
(light; cosmetic and dermatol. preps. containing creatinine and/or its derivs.)

IT Skin, disease
(pigmentation; cosmetic and dermatol. preps. containing creatinine and/or its derivs.)

IT Drug delivery systems
(topical; cosmetic and dermatol. preps. containing creatinine and/or its derivs.)

IT 57-00-1, Creatine 57-00-1D, Creatine
, derivs. 60-27-5, Creatinine 60-27-5D,
Creatinine, derivs.
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(cosmetic and dermatol. preps. containing creatinine and/or its derivs.)


RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Ajinomoto Co Inc; JP 63263060 A 1988 HCAPLUS
- (2) Anon; PATENT ABSTRACTS OF JAPAN 1989, V013(069), PC-569
- (3) Anon; PATENT ABSTRACTS OF JAPAN 2001, V2000(12)
- (4) Burke, D; JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL APPLICATIONS 1999, V732(2), P479 HCAPLUS
- (5) Charles, H; US 5968544 A 1999 HCAPLUS
- (6) Grasser, B; WO 02076408 A 2002
- (7) Heinz, K; WO 0059519 A 2000 HCAPLUS
- (8) Heinz, K; DE 19963628 A 2001
- (9) Howard Foundation; WO 02069740 A 2002 HCAPLUS
- (10) Lion Corp; JP 2000247866 A 2000 HCAPLUS
- (11) Sueddeutsche Kalkstickstoff; DE 19841385 A 2000 HCAPLUS

IT 57-00-1, Creatine
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(cosmetic and dermatol. preps. containing creatinine and/or its derivs.)

RN 57-00-1 HCAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



=> d all hitstr 163 tot

L63 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:977644 HCAPLUS
 DN 138:44726
 ED Entered STN: 29 Dec 2002
 TI Biological response modifier compositions containing carboxylic acids and creatine and taurine as anticancer agents
 IN Young, Aiping H.
 PA Lorus Therapeutics Inc., Can.
 SO PCT Int. Appl., 129 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-198
 ICS A61P037-04; A61K031-198; A61K031-195; A61K031-19; A61K031-185; A61K031-17; A61K031-14
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 1
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2002102363	A1	20021227	WO 2002-CA932	20020620 <--	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	CA 2451674	AA	20021227	CA 2002-2451674	20020620 <--	
	EP 1399140	A1	20040324	EP 2002-742593	20020620 <--	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	US 2004198819	A1	20041007	US 2004-481867	20040503 <--	
PRAI	CA 2001-2351169	A	20010620	<--		
	CA 2002-2380967	A	20020408			
	WO 2002-CA932	W	20020620			

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002102363	ICM	A61K031-198
	ICS	A61P037-04; A61K031-198; A61K031-195; A61K031-19; A61K031-185; A61K031-17; A61K031-14
US 2004198819	NCL	514/557.000; 514/561.000; 514/553.000; 514/588.000; 514/642.000
	ECLA	A61K031/14+M; A61K031/17+M; A61K031/185+M; A61K031/19+M; A61K031/197+M; A61K031/198+M; A61K031/205+M; A61K031/4168+M <--
AB	The present invention provides synthetic biol. response modifier compns. The synthetic biol. response modifier (Syn-BRM) composition comprises 3-hydroxybutyric acid 57, lactic acid 125, acetic acid 155, creatine 1.4, creatinine 22, carnitine 2.5, taurine 6.8, choline 20, and urea 815 mg/L. The compns. may addnl. comprise 40 mg/L of formic acid. The synthetic biol. response modifier compns. modify biol. response in vivo demonstrating anti-cancer activity and enhancing	

cell-mediated immune response to tumors. The invention further provides anticancer combinations comprising a synthetic biol. response modifier composition and 1 or more anticancer agents, wherein the combination improves the treatment of cancers over the composition or the anticancer agents alone. Another aspect of the present invention provides the use of synthetic biol. response modifier compns. or an anticancer combination thereof in the manufacture of a medicament or a pharmaceutical kit and in the treatment of cancer. Treatment with the composition resulted in significant delay of tumor growth compared to the saline control.

- ST biol response modifier carboxylic acid creatine taurine; anticancer
arboxylic acid creatine taurine urea
- IT Macrophage
Monocyte
(activation of; biol. response modifier compns. containing carboxylic acids
and creatine and taurine as anticancer agents)
- IT Mammary gland, neoplasm
(adenocarcinoma; biol. response modifier compns. containing carboxylic
acids and creatine and taurine as anticancer agents)
- IT Antitumor agents
B cell (lymphocyte)
Gene therapy
Human
Melanoma
T cell (lymphocyte)
(biol. response modifier compns. containing carboxylic acids and creatine
and taurine as anticancer agents)
- IT Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(biol. response modifier compns. containing carboxylic acids and creatine
and taurine as anticancer agents)
- IT Pancreas, neoplasm
(carcinoma; biol. response modifier compns. containing carboxylic acids and
creatine and taurine as anticancer agents)
- IT Carcinoma
(mammary adenocarcinoma; biol. response modifier compns. containing
carboxylic acids and creatine and taurine as anticancer agents)
- IT Osmolarity
(of pharmaceutical composition; biol. response modifier compns. containing
carboxylic acids and creatine and taurine as anticancer agents)
- IT Carcinoma
(pancreatic; biol. response modifier compns. containing carboxylic acids
and creatine and taurine as anticancer agents)
- IT 50-21-5, Lactic acid, biological studies 51-21-8, Fluorouracil
57-00-1, Creatine 57-13-6, Urea, biological studies 60-27-5,
Creatinine 62-49-7, Choline 64-18-6, Formic acid, biological studies
64-19-7, Acetic acid, biological studies 107-35-7, Taurine 300-85-6,
3-Hydroxybutyric acid 541-15-1, Carnitine 4342-03-4, Dacarbazine
15663-27-1, Cisplatin 33069-62-4, Taxol 65271-80-9, Mitoxantrone
95058-81-4, Gemcitabine 114977-28-5, Taxotere
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(biol. response modifier compns. containing carboxylic acids and creatine
and taurine as anticancer agents)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD


RE

- (1) Ferrara, F; International Journal of Antimicrobial Agents 2001,
V17(Supplement 1), PS18
- (2) Finnegan, N; European Journal of Cancer 1994, V30A(Suppl 1), PS11
- (3) Imutec Corp; WO 9628175 A 1996
- (4) Jensen, J; Journal of Surgical Research 1990, V49(4), P350 HCAPLUS
- (5) Liu, C; International Journal of Oncology 2000, V16(5), P1015 HCAPLUS
- (6) Morello, E; Cancer Investigation 2002, V20(4), P480 HCAPLUS
- (7) Wright, J; Proceedings of the American Association for Cancer Research
Annual 2002, V43, P438
- (8) Young, A; WO 0238164 A 2002 HCAPLUS


L63 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1985:179792 HCAPLUS
DN 102:179792
ED Entered STN: 02 Jun 1985
TI Unsaturated 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholines (unsaturated platelet-activating factor): aggregation of human platelets after incubation with indomethacin, creatine phosphate/creatine phosphokinase, xylocaine, and hirudine, and serotonin release after incubation with indomethacin
AU Korth, R.; Mangold, H. K.; Muramatsu, T.; Zoellner, N.
CS Med. Poliklin., Univ. Muenchen, Munich, D-8000, Fed. Rep. Ger.
SO Chemistry and Physics of Lipids (1985), 36(3), 209-14
CODEN: CPLIA4; ISSN: 0009-3084
DT Journal
LA English
CC 2-9 (Mammalian Hormones)
AB Unsaturated platelet-activating factor (PAF) [65154-06-5] aggregates thrombocytes of healthy female volunteers and releases up to 30.95% of the platelet serotonin [50-67-9] within 1 min. Indomethacin does not inhibit the aggregation but reduces the release of serotonin induced by unsaturated PAF in citrated platelet-rich plasma. Creatinine phosphate combined with creatine phosphokinase inhibits the 2nd phase, indicating a dependency on ADP release, whereas xylocaine inhibits the 1st and 2nd phase of aggregation induced by unsaturated PAF. Hirudin shows no influence on the aggregation induced by unsaturated PAF, thus eliminating a possible role for thrombin in the aggregation.
ST platelet activating factor unsaturated thrombocyte; serotonin blood platelet activating factor
IT Blood platelet
(aggregation of and serotonin release from, unsaturated platelet-activating factor effect on)
IT 50-67-9, biological studies
RL: BIOL (Biological study)
(blood platelet release of, in unsaturated platelet-activating factor response)
IT 65154-06-5
RL: BIOL (Biological study)
(unsaturated, blood platelet aggregation and serotonin release response to, mechanisms of)

L63 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1933:53719 HCAPLUS
DN 27:53719
OREF 27:4824g-h
ED Entered STN: 16 Dec 2001
TI Studies on the binding of biocolloids. XX. Proteins and crystalloids
AU Grynberg, M. D.
SO Biochemische Zeitschrift (1933), 262, 272-9
CODEN: BIZEA2; ISSN: 0366-0753
DT Journal
LA Unavailable
CC 11A (Biological Chemistry: General)
AB The combinations between H₃PO₄, guanidine, creatine and creatinine with albumin, casein, gelatin or globulin were investigated. Guanidine, which is basic, combines at the isoelectric point as well as above (ovalbumin or gelatin) or below (casein, globulin). The amphoteric creatine and creatinine combine with the proteins within a wide pH range of 3-7.3. The H₃PO₄ combines with the proteins (except gelatin) only at a pH below the isoelectric point.
IT Gelatin
(combination with H₃PO₄, guanidine, creatine and creatinine)
IT Proteins
(combinations of)

IT Albumins
 Globulins
 (combinations with H₃PO₄, guanidine, creatine and creatinine)
 IT Casein
 (compds. with H₃PO₄, guanidine, creatine and creatinine)
 IT Phosphoric acid, cholesterol esters
 (combinations with albumin, casein, gelatin or globulin)
 IT 57-00-1, Creatine 60-27-5, Creatinine
 113-00-8, Guanidine
 (combinations with albumin, casein, gelatin or globulin)
 IT 57-00-1, Creatine 60-27-5, Creatinine
 (combinations with albumin, casein, gelatin or globulin)
 RN 57-00-1 HCAPLUS
 CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 60-27-5 HCAPLUS
 CN 4H-Imidazol-4-one, 2-amino-1,5-dihydro-1-methyl- (9CI) (CA INDEX NAME)



=> b medl

FILE 'MEDLINE' ENTERED AT 13:54:19 ON 19 MAY 2005

FILE LAST UPDATED: 18 MAY 2005 (20050518/UP). FILE COVERS 1950 TO DATE.

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP
 RLOAD at an arrow prompt (=>). See also:

<http://www.nlm.nih.gov/mesh/>
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the
 MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d all 175 tot

L75 ANSWER 1 OF 2 MEDLINE on STN
 AN 88012290 MEDLINE
 DN PubMed ID: 3657037
 TI [Administration of creatine and creatinine with breast
 milk and infant milk preparations].
 Die Zufuhr von Kreatin und Kreatinin mit Frauenmilch und
 Sauglingsmilchpreparaten.

AU Hulsemann J; Manz F; Wember T; Schoch G
 CS Forschungsinstitut fur Kinderernahrung Dortmund.
 SO Klinische Padiatrie, (1987 Jul-Aug) 199 (4) 292-5.
 Journal code: 0326144. ISSN: 0300-8630.
 CY GERMANY, WEST: Germany, Federal Republic of
 DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS Priority Journals
 EM 198711
 ED Entered STN: 19900305
 Last Updated on STN: 19900305
 Entered Medline: 19871104

AB Creatine and creatinine intake can cause increased urinary creatinine excretion. To estimate the contribution of diet to creatinine excretion in infants, creatine and creatinine were determined in human milk, pasteurized cow's milk and formulas for preterm and term infants. Soy-based formulas did not contain creatine and creatinine. Average concentrations in human milk (creatine 77 [60-100] mumol/l, creatinine 52 [41-65] mumol/l) were markedly lower than in pasteurized cow's milk which contained 598 (476-640) mumol/l creatine and 105 (79-122) mumol/l creatinine. Creatine and creatinine concentrations differed widely in formulas for both preterm and term infants, from 155-559 and 33-174 mumol/l, respectively. The influence of ingested creatine on creatinine excretion should theoretically be negligible. On the other hand, based on known absorption data, creatinine from the diet should increase creatinine excretion in a 3-month-old infant up to an amount in the range of 5.3-28.4% of the endogenous production. Therefore creatinine ingestion should be taken into account when interpreting creatinine excretion in infants.

CT *Creatine: AD, administration & dosage
 Creatine: AN, analysis
 *Creatinine: AD, administration & dosage
 Creatinine: AN, analysis
 English Abstract
 Humans
 *Infant Food
 Infant Food: AN, analysis
 Infant, Newborn
 *Milk, Human
 Milk, Human: AN, analysis
 Research Support, Non-U.S. Gov't

RN 57-00-1 (Creatine); 60-27-5 (Creatinine)

L75 ANSWER 2 OF 2 MEDLINE on STN
 AN 80013280 MEDLINE
 DN PubMed ID: 384400
 TI Excretion of creatine and creatinine in feces of man.
 AU Wixom R L; Davis G E; Flynn M A; Tsutakawa R T; Hentges D J
 SO Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.), (1979 Sep) 161 (4) 452-7. Ref: 52
 Journal code: 7505892. ISSN: 0037-9727.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 197911
 ED Entered STN: 19900315
 Last Updated on STN: 19900315
 Entered Medline: 19791129

CT Check Tags: Male
 Adult
 Animals

Cattle

Creatine: AD, administration & dosage

*Creatine: ME, metabolism

Creatinine: AD, administration & dosage

*Creatinine: ME, metabolism

*Diet: AE, adverse effects

*Feces: AN, analysis

Humans

Intestines: ME, metabolism

Intestines: MI, microbiology

*Meat: AE, adverse effects

Research Support, U.S. Gov't, P.H.S.

RN 57-00-1 (Creatine); 60-27-5 (Creatinine)

=> b biosis

FILE 'BIOSIS' ENTERED AT 13:54:34 ON 19 MAY 2005

Copyright (c) 2005 The Thomson Corporation

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT

FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 18 May 2005 (20050518/ED)

FILE RELOADED: 19 October 2003.

=> d all l101 tot

L101 ANSWER 1 OF 1 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

AN 1987:251577 BIOSIS

DN PREV198784004549; BA84:4549

TI RECONSTITUTION OF FUNCTIONALLY ACTIVE ANTIBODY DIRECTED AGAINST
CREATINE KINASE FROM SEPARATELY EXPRESSED HEAVY AND LIGHT CHAINS
IN NON-LYMPHOID CELLS.AU WEIDLE U H [Reprint author]; BORGIA A; MATTES R; LENZ H; BUCKEL
PCS BOEHRINGER MANNHEIM GMBH, BIOCHEM RES CENT, BAHNHOFSTRASSE 9-15, D-8132
TUTZING, W GERSO Gene (Amsterdam), (1987) Vol. 51, No. 1, pp. 21-30.
CODEN: GENED6. ISSN: 0378-1119.

DT Article

FS BA

LA ENGLISH

ED Entered STN: 6 Jun 1987

Last Updated on STN: 6 Jun 1987

AB We report for the first time reconstitution and secretion of functionally
active antibody in non-lymphoid cells. Expression vectors for the light
and the heavy chain of a monoclonal antibody directed against
creatinine kinase (EC 2.7.3.2) were introduced into COS and CHO
Chinese hamster ovary dhfr- cells. Introduction of the expression vectors
separately gave rise to immuno-reactive material in the culture
supernatants, but only cotransfection of the expression plasmids resulted
in secretion of protein with immuno-reactivity significant antibodies
directed against mouse heavy and light chains as well as specific
antigen-binding affinity, as determined by enzyme-linked immunosorbent
assay. Secreted κ and γ chains from reconstituted antibody
were characterized by immunoadsorption and sodium dodecyl
sulfate-polyacrylamide gel electrophoresis. In COS cells, reconstituted
antibody was transiently secreted; cotransfection of κ and γ
chain expression plasmids with a dihydrofolate reductase (DHFR)-expression
plasmids into CHO dhfr-c cells gave rise to stable transformants secreting
functionally active antibody.CC Cytology - Animal 02506
Genetics - General 03502
Genetics - Animal 03506

Biochemistry methods - Nucleic acids, purines and pyrimidines 10052
 Biophysics - Bioengineering 10511
 Enzymes - Methods 10804
 Enzymes - Physiological studies 10808
 Pathology - Diagnostic 12504
 Metabolism - Nucleic acids, purines and pyrimidines 13014
 Tissue culture, apparatus, methods and media 32500
 Immunology - General and methods 34502
 IT Major Concepts
 Biochemistry and Molecular Biophysics; Cell Biology; Enzymology
 (Biochemistry and Molecular Biophysics); Genetics; Immune System
 (Chemical Coordination and Homeostasis); Methods and Techniques;
 Pathology
 IT Miscellaneous Descriptors
 EC 2.7.3.2 COS CHINESE HAMSTER OVARY CELLS CHO CHINESE HAMSTER OVARY
 CELLS DIAGNOSTIC ANTIBODY RECOMBINANT DNA TECHNOLOGY BIOTECHNOLOGY
 RN 9001-15-4 (EC 2.7.3.2)

=> b wpix

FILE 'WPIX' ENTERED AT 13:54:41 ON 19 MAY 2005
 COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 17 MAY 2005 <20050517/UP>
 MOST RECENT DERWENT UPDATE: 200531 <200531/DW>
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
 PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
 GUIDES, PLEASE VISIT:
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
 DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
 FIRST VIEW - FILE WPIFV.
 FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.
 PLEASE CHECK:
<http://thomsonderwent.com/support/dwpioref/reftools/classification/code-revision/>
 FOR DETAILS. <<<

=> d all 1121 tot

L121 ANSWER 1 OF 14 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
 AN 2005-297547 [31] WPIX
 DNC C2005-092285
 TI Agent for use on skin and/or hair to increase tanning and/or melanin
 synthesis, as polymer matrix, dressing, plaster, cloth, pad, spray or
 cosmetic or dermatological formulation, contains retinoic acid
 derivatives.
 DC A96 B07 D21 E19
 IN DIECK, K T; SCHERNER, C; SCHLENZ, K; VIETZKE, J; WOLBER, R; TOM DIECK, K
 PA (BEIE) BEIERSDORF AG
 CYC 108
 PI DE 10341663 A1 20050407 (200531)* 35 A61K007-00
 WO 2005032506 A1 20050414 (200531) GE A61K007-48
 RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE
 LS LU MC MW MZ NA NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE

DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG
 KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ
 OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG
 US UZ VC VN YU ZA ZM ZW

ADT DE 10341663 A1 DE 2003-10341663 20030908; WO 2005032506 A1 WO 2004-EP7627
 20040710

PRAI DE 2003-10341663 20030908

IC ICM A61K007-00; A61K007-48

ICS A61K007-06; A61K007-42

AB DE 10341663 A UPAB: 20050517

NOVELTY - Agent for use on skin and/or hair contains retinoic acid derivatives (I).

DETAILED DESCRIPTION - Agent for use on skin and/or hair contains retinoic acid derivatives of formula (I).

R3 = a conjugated diene group of formula (i);

R4 = carbonyl O, A1, N-(CH₂)_x-OH, N-(CHR₉)_xCH₂OH, N-(CHR₉)_x-OH, N-(CH₂)_x-OCOMe, N-OH, N-CH(R₁₁)-COR₁₀, N-CH₂CH₂-O-C(=O) or -C(=O)-NH-CH(R₁₁)-COR₁₀;

A1 = amino acid esters Ala, Ser, Gly, Val, Leu, Ile, Pro, Trp, Phe, Met, Tyr, Thr, Cys, Asn, Asp, Glu, Lys, Arg, Gln, H, Orn, Sar, Hyl, Hyp, Hse or Hcy;

x = 1-10;

R₉ = H or OH;

R₁₁ = Me, hydroxymethyl, H, prop-2-yl, isobutyl, but-2-yl, pyrrolidin-1,2-diyl, 1H-indol-3-yl-methyl, benzyl, 2-(methylthio)ethyl, 4-hydroxy-benzyl, 1-hydroxyethyl, mercaptomethyl, 2-amino-2-oxoethyl, carboxymethyl, carboxyethyl, 4-aminobutyl, 3-((amino(imino)methyl)amino)propyl, 3-amino-3-oxopropyl, H and N-Me, 3-aminopropyl, ethyl, 1H-imidazol-2-yl-methyl, butyl, propyl, 4-amino-3-hydroxy-butyl, 4-hydroxy-pyrrolidin-1,2-diyl, hydroxyethyl or 2-mercaptoethyl;

R₁₀ = OH, peptidic N-linked A1, (HN-CH(R₁₁)-CO)OH or -C(=O)-O-R₁₂;
 b = 1-6;

R₁₂ = mono to polysaccharides, preferably unitary and/or mixed mono-, di- or trisaccharides, preferably glucose, glycerose, erythrose, threose, ribose, arabinose, lyxose, xylose, allose, altrose, galactose, gulose, idose, mannose or talose;

R₁, R₂, R₅-R₇ = H, Me, Et, Pr, iPr, n-Bu, t-Bu, hydroxymethyl, hydroxyethyl, hydroxypropyl, OH and/or alkyl carboxylate having Me, Et, Pr or Bu as alkyl group;

provided that 9-retinal compound (IIa), retinal derivatives of formula (II'), and 9-retinal-alkanolamine Schiff's bases of formula (II'') are excluded.

R_a, R_b = alkyl or saturated or unsaturated alkoxy;

R = R'(OH)_n;

R' = 1-20 C hydrocarbyl; and

n = 1-5.

USE - For increasing tanning and/or melanin synthesis in the skin and/or hair, preferably as polymer matrix, skin and/or wound dressing, plaster, cloth, pad, spray, textile or especially cosmetic and/or dermatological formulation; preferably in or as an aqueous system and/or surfactant formulation for cleaning and/or care of the skin and/or hair; or as multi-, micro-, Pickering or sprayable emulsion. As pre-sun, sun protection or after-sun formulation; for topical application to skin and/or hair and protection from damaging UV radiation; for tanning or care of skin, prolonging tan color and protection from oxidative stress aging caused by age or light; and for making the hair color more intensive, inhibiting greying and/or protection from bleaching by sunlight. As shower gel, shampoo, conditioner, hair treatment, rinse, tonic or spray, make-up, skin protection, face, cleansing, sun screen, skin-care, day or night cream, gel or lotion, or cleanser (all claimed).

ADVANTAGE - The agent increases tanning and melanin synthesis and hence the intrinsic protection of the skin and hair, without using colorant and especially oxidant, e.g. hydrogen peroxide. It avoids drawbacks associated with cosmetic tanning formulations, e.g. the gradual orange to yellow-brown color change occurring with preparations containing carotene and lack of protection from sunburn with self-tanning

formulations based on dihydroxyacetone. The agent is simple to formulate, imparts a better and a natural appearance to the hair and skin, has an improved moisturizing effect, skin smoothness, spreadability, conditioning effect, an improved ability to penetrate the skin, and a better or risk-free protection of the skin and hair against UV radiation compared to prior art products. The agent has no hormonal effect.

Dwg.0/0

FS CPI

FA AB; GI; DCN

MC CPI: A12-V04A; A12-V04C; B03-A; B03-D; B03-F; B04-A10; B04-B01C1; B04-L02; B05-A01B; B05-B01P; B06-A01; B06-A02; B06-F03; B07-A03; B07-B02; B07-D09; B09-B; B10-A06; B10-A13C; B10-A17; B10-A22; B10-C02; B10-C04E; B10-D03; B10-E02; B14-N17; B14-R01; B14-R02; B14-R05; D08-B; D08-B03C; D08-B09A1; D08-B09A3; D09-E01; E05-G09A; E06-A01; E06-A02E; E06-D01; E06-F03; E07-H; E09-B; E10-A06A; E10-A13B2; E10-A17B; E10-A18B; E10-A20B; E10-A22D; E10-B01C1; E10-B02E; E10-C02B; E10-C02C2; E10-C02F; E10-C03; E10-C04A; E10-C04L1; E10-D01D; E10-D03D; E10-E02D2; E10-E02D5; E33-B

L121 ANSWER 2 OF 14 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-748578 [73] WPIX

DNC C2004-263058

TI Cosmetic or dermatological preparations containing creatinine, creatine and bioquinone, useful e.g. for combating skin aging symptoms or treating inflammatory conditions such as eczema or psoriasis.

DC B04 B05 D21

IN BIERGIESSER, H; BLATT, T; KRUSE, I;
LENZ, H; MUNDT, C; SCHMIDT, M; SCHOENROCK, U;
SCHREINER, V; STAEB, F

PA (BEIE) BEIERSDORF AG

CYC 108

PI WO 2004089326 A1 20041021 (200473)* GE 46 A61K007-48

RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE
LS LU MC MW MZ NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE
DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG
KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ
OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG
US UZ VC VN YU ZA ZM ZW

DE 10316666 A1 20041028 (200473) A61K007-48

ADT WO 2004089326 A1 WO 2004-EP50482 20040407; DE 10316666 A1 DE 2003-10316666
20030410

PRAI DE 2003-10316666 20030410

IC ICM A61K007-48

ICS A61K007-00; A61K007-06; A61K007-42; A61P017-00

AB WO2004089326 A UPAB: 20041112

NOVELTY - New cosmetic or dermatological preparations (I) contain: (A) creatinine (and/or its derivative); (B) creatine (and/or its derivative); and (C) bioquinones (optionally as component of vegetable or animal extracts).

ACTIVITY - Dermatological; Antiallergic; Antiinflammatory; Antipsoriatic; Antipruritic; Antiseborrheic; Immunosuppressant; Immunostimulant; Vulnerary; Antialopecia.

MECHANISM OF ACTION - Ceramide biosynthesis promoter; proteolytic enzyme inhibitor; intracellular DNA synthesis promoter; fibroblast and keratinocyte proliferation and differentiation promoter; antiradical.

USE - The use of (I) is claimed for:

(1) treatment and/or prophylaxis of inflammatory skin conditions and/or protection of skin against sensitivity and dryness (especially for combating atopic or seborrheic eczema, polymorphic light dermatosis, psoriasis, vitiligo, wound healing deficiency, pruritis, sensitive or irritated skin, light-induced skin damage and UV-induced immunosuppression, sensitive or hypoactive states of the skin or exoskeleton or abnormalities in desquamation or fibroblast and keratinocyte proliferation or differentiation);

(2) reduction of skin thickness;

(3) treatment and/or prophylaxis of intrinsic and/or extrinsic skin aging and/or UV induced skin damage (e.g. for combating skin degeneration symptoms (such as age-spots, wrinkles, teleangiectasia, slackness, loss of elasticity, atrophy of the epidermis, dermis, connective tissue and capillaries, fatigue and loss of luster), hyperactivity of proteolytic enzymes (e.g. metalloproteases), disorders in normal collagen, hyaluronic acid, elastin and glucosaminoglycan homeostasis, disorders in skin regeneration, intracellular DNA synthesis insufficiency (especially deficit or hypoactive states of the skin) or the effects on the skin or exoskeleton of environmental agents (e.g. smoke, smog, reactive oxygen species or free radicals));

(4) treatment and/or prophylaxis of pigmentation disorders;

(5) promotion of ceramide biosynthesis (e.g. for combating abnormalities in ceramide, lipid and energy metabolism in the skin);

(6) reinforcement of the barrier function of skin (e.g. for combating stratum corneum dysfunction, abnormalities in lipid peroxidation, transepidermal water loss and skin moisture content);

(7) treatment and/or prophylaxis of disorders in skin pH and osmolyte balance;

(8) treatment and/or prophylaxis of deficient intracellular communication in the skin (including communication via mediators and/or mechanical/physiological compounds); or

(9) treatment and/or prophylaxis of functional disorders of the exoskeleton (e.g. hair loss, hair growth deficiency, seborrhea, greasy skin or hair, comedones or dandruff) and improvement of hair structure and luster.

ADVANTAGE - (I) has a strong and lasting beneficial effect against a wide range of skin conditions (e.g. aging symptoms and UV- or ozone-induced damage) and is free of side-effects. In particular the combination of (A) - (C) has a synergistic effect (relative to (A) and (B) alone) in stabilizing energy metabolism, and thus has superior action in prophylaxis and treatment of degenerative skin and hair disorders. (A) also improves the stability of (B) in cosmetic or dermatological preparations.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B04-L02; B07-D09; B10-A06; B10-A17; B14-D07C; B14-F02C; B14-G01; B14-N17; B14-R01; B14-R02; B14-S09; D08-B03; D08-B09A

L121 ANSWER 3 OF 14 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-701630 [69] WPIX

DNN N2004-556325 DNC C2004-248228

TI Cosmetic product based on pasty formulation, used e.g. as shower gel, shampoo; skin cream, sun cream, dermatological treatment or as laundry or other detergent, has pump dispenser with product chamber of variable volume.

DC B07 D21 P24 Q33

PA (BEIE) BEIERSDORF AG

CYC 1

PI DE 20320413 U1 20040930 (200469)* 50 A45D034-00

ADT DE 20320413 U1 Application no. DE 2003-10354052 20031117, DE 2003-20320413 20031117

PRAI DE 2003-10354052 20031117; DE 2003-20320413 20031117

IC ICM A45D034-00

ICS A61K007-00; B65D047-34

AB DE 20320413 U UPAB: 20041027

NOVELTY - Cosmetic product has a paste dispenser, with a cylindrical container, sliding bottom feed piston and head piece, manually-operated feed and product chamber of variable volume, that includes a feed tube with inlet to the chamber and outlet that can be adjusted to open into the delivery tube; and a cosmetic formulation containing e.g. vitamins A, B, C, E and F, polyphenols, ubiquinone Q 10, urea and various derivatives.

DETAILED DESCRIPTION - Cosmetic product has a paste dispenser with a cylindrical container, containing a cosmetic and/or dermatological formulation, which has a bottom feed piston sliding on the inside wall of

the container under the external atmospheric pressure and a sliding head piece with product feed passage connected with the container and manually-operated feed with product chamber of variable volume. The feed has an element that can move along the container and head piece and sliding piston in the feed chamber connected to a shaft comprising a feed tube with inlet to the chamber and outlet that can be adjusted to open into the delivery tube outlet by moving the element with respect to the head piece. The cosmetic formulation contains content(s) selected from vitamins A, B, C and E and their derivatives, vitamin F, polyphenols, ubiquinone Q 10 (also in its reduced form), 2,6-di-tert.-butyl-4-methylphenol, dihydroxyacetone, niacinamide, pantothenic acid and its salts, panthenol, gamma -oryzanol, biotin, creatine, creatinine, subtilisin, alpha -glycosylrutin, allantoin, tannin, azulene, bisabolol, glycyrrhizin, hamamelin, urea, genistin, genistein, daidzein, carnitine and its derivatives and octadecendicarboxylic acid.

USE - The product is the container and pasty cosmetic and/or dermatological formulation of a cosmetic product (claimed). The cosmetics are useful as shower gel, bath formulation or shampoo; skin cream, lotion or gel, for cleaning the nails, for protecting the skin from sun or for prophylaxis, treatment and/or care of dry skin, bad to greasy skin, acne, old skin, skin aging, baby skin and/or neurodermatitis. The products can also be used for cleaning and care of articles in daily life, e.g. dishes, table and cupboard surfaces, cars, articles of clothing and washing.

ADVANTAGE - Mechanical pump dispensers have many advantages but do not provide satisfactory protection from the environment, as the volume of formulation removed during use is replaced by air, so that the formulation comes into contact with moisture and oxygen. This causes problems if the formulation contains substances that are sensitive to oxidation. hydrolysis and temperature changes. The present mechanical pump dispenser (largely) avoids this drawback and maintains the quality of even such sensitive contents.

DESCRIPTION OF DRAWING(S) - The drawing shows a longitudinal section through the dispenser.

Container 1

Head piece 3

Piston 5

Sliding piston 22

Delivery tube 32

Feed shaft 50

Feed tube 50a

Feed tube inlet 53

Feed tube outlet 58

Feed chamber 100

Dwg.1/2

FS CPI GMPI

FA AB; GI; DCN

MC CPI: B01-D02; B03-A; B03-B; B03-F; B03-H; B03-K; B06-A01; B06-F03; B07-A02B; B07-D04C; B07-D09; B10-A06; B10-A07; B10-A13C; B10-A17; B10-A22; B10-C02; B10-E02; B10-E04C; B10-J02; B14-R01; D08-B; D09-E

L121 ANSWER 4 OF 14 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-627220 [61] WPIX

DNC C2004-225650

TI Cosmetic or dermatological composition used e.g. for rejuvenating and revitalizing skin, promoting skin metabolism and combating wrinkles contains 8-hexadecene-1,16-dicarboxylic acid.

DC B05 D21 E17

IN BLATT, T; DOERING, T; GALLINAT, S; KOLBE, L; MAX, H; MUNDT, C; WOLBER, R

PA (BEIE) BEIERSDORF AG

CYC 3

PI DE 10305965 A1 20040826 (200461)* 40 A61K007-00

KR 2004073385 A 20040819 (200482) A61K007-48

CN 1535676 A 20041013 (200508) A61K007-48

ADT DE 10305965 A1 DE 2003-10305965 20030212; KR 2004073385 A KR 2004-9340 20040212; CN 1535676 A CN 2004-35244 20040212

PRAI DE 2003-10305965 20030212

IC ICM A61K007-00; A61K007-48

ICS A61K007-06; A61K007-50

AB DE 10305965 A UPAB: 20040923

NOVELTY - Cosmetic or dermatological composition (A) contains 8-hexadecene-1,16-dicarboxylic acid (I) at 0.005-20 (preferably 0.05-5, especially 0.1-3) weight%.

ACTIVITY - Dermatological; Vulnerary; Antiseborrheic; Antipruritic; Endocrine-Gen.; Antiinflammatory; Antipsoriatic.

MECHANISM OF ACTION - Collagen synthesis stimulant; Intracellular DNA synthesis promoter.

USE - (A) Is an antioxidant and radical scavenge used for restoring and/or rejuvenating the skin, revitalizing the skin, promoting skin metabolism and/or improving blood flow in the skin, tightening and/or strengthening the skin, combating wrinkles, stimulating collagen synthesis, especially for improving the 3-dimensional structure of the corium-epidermis binding site and facilitating cicatrization to reduce scar formation after epidermal wounds, and 'inspiration' of the human body and senses (all claimed).

Typically, (A) is useful in the care of aged, irritated, sunburned or shaving damaged skin, for the treatment and/or prophylaxis of light-induced skin damage, specifically polymorphic light dermatosis and for combating endogenous, chronological and exogenous skin aging symptoms. Further beneficial effects of (I) on the skin include soothing sensitive or irritated skin, stimulating intracellular DNA synthesis, improving intercellular communication and stimulating the skin's intrinsic protective and repair mechanisms, and further disorders to be combated include sensitive, greasy, blemished or dry skin, skin barrier deficiency, dandruff, pigmentation disorders, pruritis, alopecia, inflammatory skin conditions, atopic or seborrheic eczema, psoriasis and vitiligo.

ADVANTAGE - (I) has a strong and lasting beneficial effect against a wide range of skin conditions (e.g. aging symptoms and UV-induced damage) and is free of side effects.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B10-C02; B14-N17; B14-R01; D08-B03; D08-B09A1; D08-B09A3; E10-C02D2

L121 ANSWER 5 OF 14 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-554698 [54] WPIX

DNC C2004-203147

TI Cosmetic and dermatological composition, useful e.g. for restructuring and rejuvenating the skin, contains soya bean germ extract, creatinine and creatine.

DC B05 D21 E19

IN BLATT, T; GALLINAT, S; LENZ, H; MEIER ZIMMERER, C;

MUNDT, C; SCHMIDT, M; STAEB, F; VENZKE, K;

MEIER-ZIMMERER, C

PA (BEIE) BEIERSDORF AG

CYC 108

PI DE 10301632 A1 20040729 (200454)* 17 A61K007-48

WO 2004064801 A1 20040805 (200454) GE A61K007-48

RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE
LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE
DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG
KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ
OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG
US UZ VC VN YU ZA ZM ZW

ADT DE 10301632 A1 DE 2003-10301632 20030117; WO 2004064801 A1 WO 2004-EP50015 20040114

PRAI DE 2003-10301632 20030117

IC ICM A61K007-48

ICS A61K007-06; A61K007-40

AB DE 10301632 A UPAB: 20040823

NOVELTY - Cosmetic and dermatological composition (A) contains

creatinine (I) and/or its derivatives; creatine (II) and or its derivatives, or plant or animals extracts that contain them, and soya bean germ extract (B) or components (B1) isolatable from it.

ACTIVITY - Dermatological; Vulnerary; Antiinflammatory; Antipsoriatic; Immunostimulant; Antiseborrheic; Antipruritic.

No details of tests for any of these activities are given.

MECHANISM OF ACTION - None given.

USE - (A) is used for restructuring and/or rejuvenation of the skin, especially to improve the three-dimensional structure of the 'leather skin'-epidermal junction, to reduce scarring after epidermal injury and 'to inspire the human body and senses' (claimed), more generally for protection and treatment of light-sensitive skin (photodermatitis). Typical of many disclosed applications are: prevention/treatment of inflammatory skin conditions; protection of dry and sensitive skin, e.g. in cases of eczema, polymorphic photodermatitis, psoriasis and vitiligo, wound-healing disorders, itching, UV-induced immune suppression, altered desquamation, altered proliferation of fibroblasts and keratinocytes, sensitive or hypoactive states and for reducing thickness of the skin; also treatment/prevention of skin aging, pigmentation disorders, alterations in pH value or osmolyte balance, or in cell-cell communication; for improving barrier function, and to treat hair loss, seborrhea and comedones; and protection against pollutants (including smoke, reactive oxygen species or free radicals). (A) stimulates synthesis of collagen, hyaluronic acid, elastin, ceramides and DNA, so promotes cell renewal and regeneration in the skin; stimulates the skin's own protective and repair mechanisms, and probably act as antioxidants and free radical scavengers.

ADVANTAGE - The compositions provide long-lasting protection without side effects.

Dwg.0/0

FS

CPI

FA

AB; DCN

MC

CPI: B03-H; B04-A08; B04-A10; B04-C03B; B05-C08; B06-A01; B07-D09; B10-A17; B10-B01B; B10-E04C; B10-E04D; B10-G02; B10-J02; B14-C03; B14-G01; B14-N17; B14-R02; D08-B09A1; D08-B09A3; E06-A01; E07-D09D; E10-A17B; E10-B01C1; E10-E04H; E10-E04L5; E10-G02G2; E33-A03

L121 ANSWER 6 OF 14 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-518848 [50] WPIX

DNN N2004-411021 DNC C2004-191491

TI Pressure-sensitive adhesive matrix, useful e.g. in transdermal therapeutic systems or cosmetic pads or plasters, containing gel-forming polymer, marine algae extract, alcohol, water and optionally active agent.

DC A96 B04 D21 D22 G03 P34

IN KRUSE, I; WOELLER, K H; WOLBER, R; WOELLER, K

PA (BEIE) BEIERSDORF AG

CYC 28

PI DE 10260872 A1 20040701 (200450)* 32 C08J003-075

WO 2004058211 A1 20040715 (200450) GE A61K007-48

RW: AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO

SE SI SK TR

W: JP US

ADT DE 10260872 A1 DE 2002-10260872 20021223; WO 2004058211 A1 WO 2003-EP14792 20031223

PRAI DE 2002-10260872 20021223

IC ICM A61K007-48; C08J003-075

ICS A61K047-32; A61K047-36; A61L015-28; A61L015-44; A61P017-02;

C08L005-00; C08L033-02

AB DE 10260872 A UPAB: 20040805

NOVELTY - A new pressure-sensitive adhesive matrix (I) comprises: (a) at least one polymer forming a gel in water; (b) water; (c) an extract of marine algae; and (d) a mono- or polyhydric alcohol.

ACTIVITY - Dermatological; Antiinflammatory; Vulnerary.

MECHANISM OF ACTION - None given.

USE - The use of (I) is claimed:

(1) in cosmetic or dermatological pads or plasters;

- (2) for general skin care;
- (3) as an active agent-containing dosage for topical or buccal use or as a component of a (preferably monolithic) transdermal therapeutic system; or
- (4) for prophylaxis and treatment of skin aging symptoms (especially wrinkles), pigmentation disorders (especially age-spots) or inflammatory/irritative skin disorders (especially shaving rash and/or sunburn).

Medicinal plasters and cosmetic or dermatological pads or plasters containing (I) are also claimed.

ADVANTAGE - The matrices (I) can be doped with a wide range of hydrophilic or hydrophobic, cosmetic, dermatological and/or medicinal active agents, and show skin-care, moisturizing and cooling properties even in the absence of added active agents. They are easy to apply and have a pleasant, 'silky' feeling on the skin. The combination of the algal extract (c) and alcohol (d) has a synergistic effect in providing gel matrices of the required elasticity.

Dwg.0/0

FS CPI GMPI
 FA AB; DCN
 MC CPI: A04-F04B; A04-F06E5; A08-C; A12-V03A; A12-V04C; B04-A08C2; B04-A10; B04-C02D; B04-C03B; B04-L02; B05-C08; B06-A01; B07-A01; B07-A02B; B07-B03; B07-D09; B10-A09B; B10-A17; B10-B03B; B10-C02; B10-E04C; B10-E04D; B12-M02D; B14-A01; B14-C03; B14-N17; D08-B09A; D09-C04B; G03-B02D1

L121 ANSWER 7 OF 14 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-392995 [37] WPIX

DNC C2004-147100

TI Cosmetic or dermatological compositions with an aqueous phase contain **creatine**, **creatinine** and/or a **creatine** derivative such as salt or ester and have a reduced crystallization tendency.

DC A96 D21 E16

PA (BEIE) BEIERSDORF AG

CYC 1

PI DE 20318417 U1 20040401 (200437)* 26 A61K007-00

ADT DE 20318417 U1 DE 2003-20318417 20031126

PRAI DE 2003-20318417 20031126

IC ICM A61K007-00

AB DE 20318417 U UPAB: 20040611

NOVELTY - Cosmetic or dermatological compositions with an aqueous phase contain **creatine**, **creatinine** and/or a **creatine** derivative comprising **creatine-phosphate**, **-sulfate**, **-acetate** or **-ascorbate** or a **creatine** derivative esterified at the carboxy group by mono- or poly-functional alcohols.

DETAILED DESCRIPTION - The quotient (Q) (= product of water concentration and water activity)/(sum of concentrations of **creatine**, **creatinine** and/or a **creatine** derivative) being at least 40.

ACTIVITY - Dermatological; Anti-inflammatory.

MECHANISM OF ACTION - None given in the specification.

USE - In cosmetics as a skin barrier (e.g. against external influences or loss of fats) or in the treatment of the symptoms of UV- or ozone-induced skin damage (e.g. wrinkles or pigmentation), inflammations or degenerative (e.g. dry) skin conditions.

ADVANTAGE - There is a reduced tendency for the **creatine** to form crystals.

Dwg.0/0

FS CPI
 FA AB; DCN
 MC CPI: A12-V01; A12-V04C; D08-B09A1; D08-B09A3; D09-E; E05-G06; E07-A02B; E07-D09D; E10-A17B

L121 ANSWER 8 OF 14 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-366245 [35] WPIX

DNC C2004-138380
 TI Cosmetic or dermatological compositions with an aqueous phase contain **creatine, creatinine and/or a creatine derivative** together with an electrolyte.
 DC A96 D21 E16
 PA (BEIE) BEIERSDORF AG
 CYC 1
 PI DE 20318415 U1 20040401 (200435)* 28 A61K007-00
 ADT DE 20318415 U1 DE 2003-20318415 20031126
 PRAI DE 2003-20318415 20031126
 IC ICM A61K007-00
 AB DE 20318415 U UPAB: 20040603
 NOVELTY - Cosmetic or dermatological compositions with an aqueous phase contain
 (a) **creatine, creatinine and/or a creatine derivative** comprising **creatine-phosphate, -sulfate, -acetate or -ascorbate** or a **creatine derivative** esterified at the carboxy group by mono- or poly-functional alcohols; and
 (b) an aqueous phase containing dissolved electrolyte to give an aqueous phase ion concentration at least 0.050 mol/l.
 ACTIVITY - Dermatological; Anti-inflammatory
 MECHANISM OF ACTION - None given in the specification.
 USE - In cosmetics as a skin barrier (e.g. against external influences or loss of fats) or in the treatment of the symptoms of UV- or ozone-induced skin damage (e.g. wrinkles or pigmentation), inflammations or degenerative (e.g. dry) skin conditions.
 ADVANTAGE - There is a reduced tendency for the **creatine** to form crystals and the emulsions are stable.
 Dwg.0/0
 FS CPI
 FA AB; DCN
 MC CPI: A12-V04C; D08-B09A1; D08-B09A3; D09-E; E05-A; E05-B01; E05-B03; E05-G06; E05-L02A; E05-L03; E06-D05; E07-D09D; E10-A09B; E10-A17B; E10-A22G; E10-B01C1; E10-B02; E10-C02A; E10-C02F; E10-C04; E31-K05; E31-Q06; E31-Q07; E32-A04; E33; E34; E35

L121 ANSWER 9 OF 14 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
 AN 2004-366244 [35] WPIX
 DNC C2004-138379
 TI Cosmetic or dermatological compositions contain **creatine, creatinine and/or a creatine derivative** together with a hydrocolloid.
 DC A96 D21 E16
 PA (BEIE) BEIERSDORF AG
 CYC 1
 PI DE 20318414 U1 20040401 (200435)* 28 A61K007-00
 ADT DE 20318414 U1 DE 2003-20318414 20031126
 PRAI DE 2003-20318414 20031126
 IC ICM A61K007-00
 ICS A61K007-42
 AB DE 20318414 U UPAB: 20040603
 NOVELTY - A cosmetic or dermatological composition contains
 (a) **creatine, creatinine and/or a creatine derivative**; and
 (b) one or more hydrocolloids.
 ACTIVITY - Dermatological; Anti-inflammatory
 MECHANISM OF ACTION - None given in the specification.
 USE - In cosmetics as a skin barrier (e.g. against external influences or loss of fats) or in the treatment of the symptoms of UV- or ozone-induced skin damage (e.g. wrinkles or pigmentation), inflammations or degenerative (e.g. dry) skin conditions.
 ADVANTAGE - There is a reduced tendency for the **creatine** to form crystals.
 Dwg.0/0
 FS CPI
 FA AB; DCN

MC CPI: A12-V04C; D08-B09A1; D08-B09A3; D09-E; E07-D09D; E10-A17B

L121 ANSWER 10 OF 14 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-318263 [30] WPIX

DNC C2004-120925

TI Actives combination for use as a cosmetic or dermatological composition contains **creatine** and/or **creatinine** together with phenoxyethanol and optionally also glycerol.

DC D21 E14 E16

PA (BEIE) BEIERSDORF AG

CYC 1

PI DE 20318413 U1 20040401 (200430)* 27 A61K007-40

ADT DE 20318413 U1 DE 2003-20318413 20031126

PRAI DE 2003-20318413 20031126

IC ICM A61K007-40

ICS A61K007-00; A61K007-48

AB DE 20318413 U UPAB: 20040511

NOVELTY - An actives combination comprises

(a) **creatine** and/or **creatinine**;

(b) phenoxyethanol; and optionally also

(c) glycerol.

ACTIVITY - Dermatological; Antiinflammatory

MECHANISM OF ACTION - None given in the specification.

USE - As a cosmetic or dermatological composition (claimed), e.g. in cosmetics as a skin barrier (e.g. against external influences or loss of fats) or in the treatment of the symptoms of UV- or ozone-induced skin damage (e.g. wrinkles or pigmentation), inflammations or degenerative (e.g. dry) skin conditions.

ADVANTAGE - There is a reduced tendency for the **creatine** to form crystals.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: D08-B09A1; D08-B09A3; D09-E; E07-D09D; E10-A17B; E10-E04M1

L121 ANSWER 11 OF 14 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-306784 [29] WPIX

DNC C2004-116480

TI Combination useful in cosmetic or dermatological compositions comprises **creatine** and/or **creatinine** and one or more retinoids.

DC B05 D21 E15

PA (BEIE) BEIERSDORF AG

CYC 1

PI DE 20318416 U1 20040408 (200429)* 33 A61K007-40

ADT DE 20318416 U1 DE 2003-20318416 20031126

PRAI DE 2003-20318416 20031126

IC ICM A61K007-40

ICS A61K007-00; A61K007-48

AB DE 20318416 U UPAB: 20040505

NOVELTY - Combination of **creatine** and/or **creatinine** and one or more retinoids is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a cosmetic or dermatological composition containing a combination as above.

ACTIVITY - Dermatological; Antiinflammatory. No biological data given.

MECHANISM OF ACTION - None given.

USE - The combination is useful in cosmetic or dermatological compositions for treating or preventing symptoms of UV- and ozone-induced skin damage and inflammatory or degenerative skin conditions (unspecified).

ADVANTAGE - The composition has a long-lasting action against skin aging with no risk of side effects and has a reduced tendency to form **creatine** crystals.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B03-A; B07-D09; B10-A17; B14-C03; B14-N17; B14-R01; B14-R05;
D08-B09A; E10-A17B; E10-E04M1

L121 ANSWER 12 OF 14 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2003-291237 [29] WPIX

CR 2003-291236 [29]

DNC C2003-075886

TI Cosmetic or dermatological preparations containing creatinine and creatine, useful e.g. for combating skin aging symptoms or treating inflammatory conditions such as eczema or psoriasis.

DC B03 D21 E13

IN BIERGIESSER, H; BLATT, T; KRUSE, I;
LENZ, H; MUNDT, C; SCHMIDT, M; SCHOENROCK, U;
SCHREINER, V; STAEB, F; SCHONROCK, U; STAB, F

PA (BEIE) BEIERSDORF AG

CYC 32

PI DE 10136077 A1 20030213 (200329)* 15 A61K007-48

WO 2003011242 A1 20030213 (200329) GE A61K007-48

RW: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK
TR

W: JP US

EP 1414402 A1 20040506 (200430) GE A61K007-48

R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LT LU LV MC
MK NL PT RO SE SI SK TR

US 2004241197 A1 20041202 (200481) A61K007-00

JP 2005503373 W 20050203 (200516) 55 A61K007-00

ADT DE 10136077 A1 DE 2001-10136077 20010725; WO 2003011242 A1 WO 2002-EP8125
20020722; EP 1414402 A1 EP 2002-764746 20020722, WO 2002-EP8125 20020722;
US 2004241197 A1 Cont of WO 2002-EP8124 20020722, Cont of WO 2002-EP8125
20020722, US 2004-767962 20040126; JP 2005503373 W WO 2002-EP8125
20020722, JP 2003-516474 20020722

FDT EP 1414402 A1 Based on WO 2003011242; JP 2005503373 W Based on WO
2003011242

PRAI DE 2001-10136077 20010725

IC ICM A61K007-00; A61K007-48

ICS A61K031-198; A61K031-4168; A61K031-664; A61P017-00; A61P017-02;
A61P017-04; A61P017-06; A61P017-14; A61P017-16

AB DE 10136077 A UPAB: 20050308

NOVELTY - Cosmetic or dermatological preparations (A) containing a combination of creatinine (and/or its derivatives) (I) and creatine (and/or its derivatives) (II) are new.

ACTIVITY - Dermatological; Antiallergic; Antiinflammatory; Antipsoriatic; Antipruritic; Antiseborrheic; Immunosuppressant; Immunostimulant; Vulnerary; Antialopecia.

No suitable biological data available.

MECHANISM OF ACTION - Ceramide biosynthesis promoter; proteolytic enzyme inhibitor; intracellular DNA synthesis promoter; fibroblast and keratinocyte proliferation and differentiation promoter; antiradical.

USE - The use of (A) is claimed for: (a) treatment and/or prophylaxis of inflammatory skin conditions and/or protection of skin against sensitivity and dryness (e.g. for combating atopic or seborrheic eczema, polymorphic light dermatosis, psoriasis, vitiligo, wound healing deficiency, pruritis, sensitive or irritated skin, light-induced immunosuppression, sensitive or hypoactive states of the skin or exoskeleton or abnormalities in desquamation or fibroblast and keratinocyte proliferation or differentiation); (b) treatment and/or prophylaxis of intrinsic and/or extrinsic skin aging and/or UV induced skin damage (e.g. for combating skin degeneration symptoms (such as age-spots, wrinkles, teleangiectasis, slackness, loss of elasticity, atrophy of the epidermis, dermis, connective tissue and capillaries, 'fatigue' and loss of luster), hyperactivity of proteolytic enzymes (e.g. metalloproteases), disorders in normal collagen, hyaluronic acid, elastin and glucosaminoglycan homeostasis, intracellular DNA synthesis insufficiency (especially deficit or hypoactive states of the skin) or the effects on the skin or exoskeleton of environmental agents (e.g. smoke, smog, reactive oxygen species or free radicals)); (c) treatment and/or